Developing Statistical Methods For Data From Platforms Measuring Gene Expression by Jia, Gaoxiang
Southern Methodist University
SMU Scholar
Statistical Science Theses and Dissertations Statistical Science
Spring 2018
Developing Statistical Methods For Data From
Platforms Measuring Gene Expression
Gaoxiang Jia
Southern Methodist University, gjia@smu.edu
Follow this and additional works at: https://scholar.smu.edu/hum_sci_statisticalscience_etds
Part of the Applied Statistics Commons, Biostatistics Commons, Statistical Methodology
Commons, and the Statistical Models Commons
This Dissertation is brought to you for free and open access by the Statistical Science at SMU Scholar. It has been accepted for inclusion in Statistical
Science Theses and Dissertations by an authorized administrator of SMU Scholar. For more information, please visit http://digitalrepository.smu.edu.
Recommended Citation
Jia, Gaoxiang, "Developing Statistical Methods For Data From Platforms Measuring Gene Expression" (2018). Statistical Science Theses
and Dissertations. 1.
https://scholar.smu.edu/hum_sci_statisticalscience_etds/1
DEVELOPING STATISTICAL METHODS FOR DATA FROM
PLATFORMS MEASURING GENE EXPRESSION
Approved by:
Dr. Xinlei Wang
Professor of Statistics
Dr. Guanghua Xiao
Associate Professor of Biostatistics
Dr. Daniel Heitjan
Professor of Biostatistics
Dr. Lynne Stokes
Professor of Statistics
DEVELOPING STATISTICAL METHODS FOR DATA FROM
PLATFORMS MEASURING GENE EXPRESSION
A Dissertation Presented to the Graduate Faculty of the
Dedman College of Humanities and Sciences
Southern Methodist University
in
Partial Fulfillment of the Requirements
for the degree of
Doctor of Philosophy
with a
Major in Biostatistics
by
Gaoxiang Jia
B.S., Shandong University, China, 2012
M.S., University of Texas Southwestern Medical Center, 2014
M.S., Southern Methodist University, 2017
May 19, 2018
Copyright (2018)
Gaoxiang Jia
All Rights Reserved
ACKNOWLEDGMENTS
Firstly, I would like to express my sincere gratitude to my advisors Drs. Xinlei Wang and
Guanghua Xiao. They are the greatest mentors I could imagine: worked with me closely
on my research and always provided the help and advice I needed. Their enthusiasm for
statistics and science inspired me in all the time of my research. Without their training, I
would not be able to become a statistician. They do not only train me in statistics, but also
showed me how to treat people with respect and kindness.
Secondly, I would like to thank the rest of my thesis committee members Drs. Daniel
Heitjan and Lynne Stokes, for their insightful comments on my dissertation and dedication
to organizing this new joint biostatistics PhD program between SMU and UTSW. I also want
to thank all the other faculty members in the Department of Statistical Science at SMU for
their excellent teaching and help during my PhD study. My appreciation also goes to the
faculty members who have helped me during my research and statistical consulting projects
in the Department of Clinical Science at UTSW.
I would also like to thank my friends Dateng Li, Zhiyun Ge and Zhengyang Zhou for
helping me on my coursework and research. Thanks for making my life at SMU enjoyable
even when the pressure from courses and research projects is high.
I would like to thank my friends Kai Huang, Tao Wang and his wife, Yulei Zhang and
his wife, Yandan Yang, Yixun Xing, Xue Li, Lin Qiu and Xiujun Zhu for their help on my
application to the PhD programs at UTSW or SMU and/or their suggestions and encour-
agement on my career.
Last but not the least, I would like to express my gratitude to my wife Jinyan Chan, my
parents and other family members for always loving, supporting and believing in me.
iv
Jia, Gaoxiang B.S., Shandong University, China, 2012
M.S., University of Texas Southwestern Medical Center, 2014
M.S., Southern Methodist University, 2017
Developing Statistical Methods for Data from
Platforms Measuring Gene Expression
Doctor of Philosophy degree conferred May 19, 2018
Dissertation completed February 19, 2018
This research contains two topics: (1) PBNPA: a permutation-based non-parametric
analysis of CRISPR screen data; (2) RCRnorm: an integrated system of random-coeﬃcient
hierarchical regression models for normalizing NanoString nCounter data from FFPE sam-
ples.
Clustered regularly-interspaced short palindromic repeats (CRISPR) screens are usually
implemented in cultured cells to identify genes with critical functions. Although several
methods have been developed or adapted to analyze CRISPR screening data, no single spe-
cific algorithm has gained popularity. Thus, rigorous procedures are needed to overcome the
shortcomings of existing algorithms. We developed a Permutation-Based Non-Parametric
Analysis (PBNPA) algorithm, which computes p-values at the gene level by permuting
sgRNA labels, and thus it avoids restrictive distributional assumptions. Although PBNPA
is designed to analyze CRISPR data, it can also be applied to analyze genetic screens im-
plemented with siRNAs or shRNAs and drug screens. We compared the performance of
PBNPA with competing methods on simulated data as well as on real data. PBNPA out-
performed recent methods designed for CRISPR screen analysis, as well as methods used for
analyzing other functional genomics screens, in terms of Receiver Operating Characteristics
(ROC) curves and False Discovery Rate (FDR) control for simulated data under various
 Advisors:  Drs. Xinlei Wang & Guanghua Xiao
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settings. Remarkably, the PBNPA algorithm showed better consistency and FDR control on
published real data as well.
Formalin-fixed, paraﬃn-embedded (FFPE) samples have great potential for biomarker
discovery, retrospective studies, and diagnosis/prognosis of diseases. However, their appli-
cation is hindered by the unsatisfactory performance of traditional gene expression profiling
techniques on damaged RNAs. NanoString nCounter platform is well suited for profiling of
FFPE samples and measures gene expression with high sensitivity, which may greatly facil-
itate realization of scientific and clinical values of FFPE samples. However, methodological
development for normalization, a critical step when analyzing this type of data, is far be-
hind that for traditional technologies such as microarray. Existing methods designed for the
platform use information from diﬀerent types of internal controls separately and rely on an
overly-simplified assumption that expression of housekeeping genes is constant across samples
for global scaling. We construct an integrated system of random-coeﬃcient hierarchical re-
gression models to capture main patterns and characteristics observed from NanoString data
of FFPE samples, and develop a Bayesian approach to estimate parameters and normalize
gene expression across samples. Our method, labeled RCRnorm, incorporates information
from all aspects of the experimental design, and simultaneously removes biases from various
sources. Further, it eliminates the unrealistic assumption on housekeeping genes and oﬀers
great interpretability. Simulation and applications showed its superior performance.
vi
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Chapter 1
PBNPA: A PERMUTATION-BASED NON-PARAMETRIC ANALYSIS OF CRISPR
SCREEN DATA
1.1. Introduction
1.1.1. CRISPR mediated genomic screens and other type of genomic screens
The CRISPR (clustered regularly-interspaced short palindromic repeats) interference
technique is widely used in biomedical studies to investigate gene functions. Large-scale
screening with this technique has become a powerful tool in identifying cancer-promoting
genes, drug-resistant genes, and genes that play pivotal roles in various biological processes
(Shalem et al., 2015; Hart et al., 2015; Wang et al., 2014). The CRISPR/Cas9 system is com-
posed of sgRNAs (single guide RNA) and Cas9s (CRISPR associated protein 9); an sgRNA
contains around a 20-bp guide sequence that complements a DNA sequence and thus targets
a gene of interest, and a Cas9 is a nuclease that induces double-strand breaks in the DNA
and results in non-homologous end joining (NHEJ) repair. NHEJ is an error-prone repair
mechanism that usually introduces an indel mutation that is highly likely to cause a coding
frameshift, which leads to a premature stop codon and initiates the nonsense-mediated de-
cay of the transcribed mRNA (Shalem et al., 2015). Thus, the CRISPR system abolishes
the gene function by interfering with gene expression from the DNA level. This is more
powerful than siRNA (small interfering RNA) or shRNA (short hairpin RNA) screens. An
siRNA contains 20 ~ 25 bp short synthesized RNAs that function in the RNA interference
pathway, and it cannot be integrated into a host genome. An shRNA contains synthesized
double-stranded RNA molecules with a tight hairpin turn, which can be integrated into
a host genome; however, it inhibits the gene function at the mRNA level (Gilbert et al.,
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2014). All three types of screens are usually implemented on cultured cells: siRNA screens
are carried out in multi-well plates with each well containing one or several siRNAs tar-
geting the same gene, and the signal in each well is collected as the read for that well; by
contrast, CRISPR and shRNA screens are carried out in a pooled manner, where a mix-
ture of lentivirus that contains RNAi reagents (either shRNA or sgRNA) targeting diﬀerent
genes is transfected into the same plate of cultured cells, and the microarray or next gen-
eration sequencing (NGS) technique can be used to collect reads. Cas9-sgRNA screens are
performed with pre-designed sgRNA libraries that contain sgRNA redundancy. Generally,
multiple sgRNAs (usually ranging from 3-10) with diﬀerent sequences that target distinct
locations on the same gene are utilized to ensure screening accuracy (Shalem et al., 2015).
All genome-wide CRISPR screens use cell growth as a phenotypic measure. Based on the
goal of the screens, they can be divided into positive selection screens and negative selection
screens (Shalem et al., 2014). Positive screens aim to identify genes that inhibit cell growth
in certain circumstances or that sensitize cells to a drug treatment or toxin. For example,
genes protecting cells against toxins, which are likely to be receptors for the toxins, or genes
involved in downstream signaling pathways (Koike-Yusa et al., 2014), may be targeted by
positive screens. Under a strong selective pressure, cells with sgRNAs that confer resistance
against that pressure would be enriched, and thus their signals are often strong and easy to
detect. Negative selection screens aim to identify genes that promote cell growth or house-
keeping genes (Morgens et al., 2016). In this scenario, cells that carry sgRNAs targeting
such genes will be depleted during selection. Signals from negative screens are typically not
as strong as those from positive screens, because the depletion level is usually mild and the
number of depleted sgRNAs is large when considering the number of housekeeping genes
(and thus they can be hard to separate from the background.)
1.1.2. Review of existing methods for analyzing CRISPR screen data
There are existing methods that can be used to analyze genome-wide RNA interfering
screening results, including RSA (Konig et al., 2007), RIGER (Luo et al., 2008), MAGeCK
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(Li et al., 2014), ScreenBEAM (Yu et al., 2016), etc. The Redundant siRNA Activity (RSA)
method was originally developed to analyze data generated by large-scale small interfering
RNA (siRNA) screens in mammalian cells (Konig et al., 2007). RSA calculates a p-value
for each gene based on an iterative hypergeometric distribution formula, where a smaller
p-value indicates the gene is more likely to have higher activity. RNAi Gene Enrichment
Ranking (RIGER) was originally designed to identify essential cell genes in genome-scale
pooled shRNA screens (Luo et al., 2008). It calculates the rank of each sgRNA based on
a signal-to-noise metric and then synthesizes information on sgRNAs targeting the same
gene in a way similar to that of Gene Set Enrichment Analysis to rank genes (Subramanian
et al., 2005). Model-based Analysis of Genome-wide CRISPR/Cas9 Knockout (MAGeCK)
and Screening Bayesian Evaluation and Analysis Method (ScreenBEAM) were both designed
to analyze CRISPR screen data. MAGeCK evaluates sgRNAs based on p-values calculated
from fitting a negative binomial model (Li et al., 2014), and then the ranks of sgRNAs tar-
geting the same gene are combined with a modified version of robust ranking aggregation
(RRA) called -RRA. ScreenBEAM assesses the gene level activity with Bayesian hierarchical
models (Yu et al., 2016), in which within-gene variances were modeled as random eﬀects.
Among the above methods, RIGER, MAGeCK and ScreenBEAM can perform both positive
and negative selection. In addition, several algorithms used for analysis of Next Generation
Sequencing (NGS) data, such as edgeR (Robinson and McCarthy, 2010), DESeq (Anders
and Huber, 2012) baySeq (Hardcastle and Kelly, 2010), NOISeq (Tarazona et al., 2012) and
SAMseq (Li and Tibshirani, 2013), can also be used to analyze RNAi screening data. Al-
though such methods can only assign ranks at the sgRNA level, they can be used to conduct
gene-level inference (Li et al., 2014) when combined with existing methods of integrating
group information. It is worth noting that NOISeq and SAMseq both take nonparametric
approaches. Unlike our method that is based on permutation, SAMseq mainly relies on the
two-sample Wilcoxon statistic to estimate the significance; and NOISeq assesses the signif-
icance of the treatment eﬀect with the reference distribution generated by comparing reads
of each gene in samples under the same condition.
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1.1.3. Motivation of our study
Although many CRISPR screen analysis methods are available, no single specific algo-
rithm has gained popularity from researchers, mainly due to one or more of the drawbacks
listed below: (1) Distributions assumed are doubtful or incorrect and thus incapable of mod-
eling data variability from diﬀerent sources. Researchers generally use negative binomial or
Poisson distributions to model read counts from NGS (Seyednasrollah et al., 2015). However,
these distributions do not reflect certain characteristics of NGS data generating processes and
are weak in handling over-dispersion. (2) Most studies compared their model performance
using some ‘oracle’ datasets. However, the performance may be compromised when general-
izing these methods to datasets from diﬀerent conditions or platforms. This is reflected by
the fact that the number of consistently identified genes across diﬀerent algorithms is often
small (Diaz et al., 2015). (3) Published methods usually have loose or no false discovery rate
(FDR) control. FDR reflects the rate of type I errors when performing multiple hypothesis
tests and influences the credibility of the tests if not carefully controlled. False discovery
is a big concern for functional genomic studies when a large number of statistical tests are
performed (Pawitan et al., 2005). The above-mentioned methods tend to overlook FDR
or be ineﬀective in controlling it, as will be shown in detail in the Real Data Application
section. Without stringent FDR controlled p-values, it is diﬃcult to evaluate the statistical
significance of selected genes.
1.1.4. Research overview
Our proposed method, Permutation-Based Non-Parametric Analysis (PBNPA) of CRISPR
screen data, mitigates the three major drawbacks of existing CRISPR methods. First, PB-
NPA computes p-values at the gene level by permuting sgRNA labels, and thus it avoids
restrictive distributional assumptions. Second, PBNPA shows superior performance to other
algorithms in simulation using data generated to mimic the NGS sequencing process, which
avoids overfitting based on specific datasets. Application to real data confirms better con-
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sistency of PBNPA. Last, our data application reveals that PBNPA outperformed its com-
petitors in terms of FDR control.
1.2. Methods
1.2.1. A permutation-based non-parametric method for calculating p-values for genes
In a CRISPR screen dataset, assume Yij is the read count for the jth sgRNA in the
library under condition i, where j = 1, 2, · · · , J indexes sgRNAs in the library; and i =
0, 1 indexes two experimental conditions, with i = 0 for the control and i = 1 for the
treatment. We use Ig to denote the index set of the sgRNAs that target the same gene g
and
SG
g=1 Ig = {1, 2, · · · , J}, where g = 1, 2, · · · , G and G is the total number of genes in
the library. Raw read counts in each condition i were normalized by multiplying a factor of
mean(
PJ
j=0 Y0j,
PJ
j=1 Y1j)/
PJ
j=1 Yij. This makes total read counts in each condition equal
without losing any useful information. Our PBNPA algorithm is outlined below.
1. For each sgRNA j (j = 1, 2, · · · , J), calculate the natural logarithm fold change of
normalized read counts: rj = log(Y1j/Y0j). Then for each gene g, use the median of
rj’s (j 2 Ig) as the R score, denoted by Rg.
2. Randomly permute gene labels while holding (Yoj, Y1j) pairs unchanged to get permu-
tated R scores for each gene, denoted by R⇤g1’s, where g = 1, 2, · · · , G.
3. Repeat step 2 for T times and pool all R⇤gt’s over the T permutations and all genes to
form a null distribution of R.
4. Calculate the p value for gene g if it is a positively selected gene as:
p = (#of permuted R scores >Rg)/(total # of permuted R scores);
and the value for gene if it is a negatively selected gene as:
p = (#of permuted R scores <Rg)/(total # of permuted R scores).
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5. After getting p values for all genes, remove genes with p values smaller than a threshold,
which are considered to be significant genes. Then repeat step 2 and 3 to get the null
distribution with significant genes removed. Get updated p values for each gene as
described in step 4.
6. Use the Benjamini-Hochberg procedure to control FDR (Benjamini and Hochberg,
1995).
In this algorithm, the median log fold change of sgRNAs targeting a gene is used as the score
of that gene, which makes it more robust against any outliers and influences from potential
oﬀ-target eﬀects. In step 5, we remove a small portion of genes with the purpose of removing
any significant genes to get a more accurate estimate of the null distribution , as the null
distribution is likely to be distorted if these significant genes are kept in the permutation
process.
1.2.2. Combining p-values to handle replicates
A CRISPR screen experiment may contain several replicates. We analyzed each replicate
using the proposed algorithm and then employed Fisher’s method to combine p-values from
replicates for each gene (Brown, 1975; Rau et al., 2014). According to Fisher’s method, the
statistic  2PSs=1 ln pgs, with pgs representing gene g’s p value from the sth replicate, follows
an  2 distribution with 2S degrees of freedom under the null hypothesis Ho: gene g has no
eﬀect, from which a combined p value for each gene g is obtained (Brown, 1975).
1.3. Simulation studies
1.3.1. Simulation strategy
To mimic the nature of RNA-seq experiments, the read counts of all sgRNAs under a
given condition were generated from a Dirichlet-multinomial (DM) distribution. Considering
the experimental setup of CRISPR screening with RNA-seq, each sgRNA in a library can
be viewed as an outcome category in a multinomial distribution when the total read count
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(sequencing depth) is fixed. However, the literature indicates that multinomial distributions
are inadequate to model the extra variability that is usually observed in NGS data (Chen and
Li, 2013; Bonafede et al., 2016). To account for over-dispersion, the probability vector of an
NGS read falling into the diﬀerent sgRNA categories is modeled as random variables from a
Dirichlet distribution. After combining the multinomial model with the Dirichlet model, the
mixture model is a Dirichlet-multinomial model with the probability mass function (PMF)
shown below:
f(Yi) =
 (Yi+ + 1) ( i+)
 (Yi+ +  i+)
JY
j=1
 (Yij +  ij)
 (Yij + 1) ( ij)
where Yi = [Yi1, Yi2, · · · , YiJ ], Yi+ =
PJ
j Yij,  i+ =
PJ
j  ij with  ij’s being the parameters of
the DM distribution; and E(Yij) = Yi+  ij i+ and V ar(Yij) = Yi+
 ij
 i+
(1    ij i+ )(
Yi++ i+
1+ i+
) (Chen
and Li, 2013; Tu, 2014). Compared to the variance of the multinomial model, the variance of
the DM model is increased by a factor of Yi++ i+1+ i+ . When the total read count Yi+ is fixed,  i+
controls the degree of overdispersion with a smaller value indicating larger overdispersion.
To simulate read counts for a screen experiment, we first generated  0j’s for a control
sample from a negative binomial distribution NB(q, p) where q is the number of successful
trials to be reached and p is the probability of success in each trial. We set q = 3 and p = 0.08
so that the generated DM read counts are right skewed, which approximately mimics real
data. We link  ij to the eﬀect of sgRNA j through the relationship  ij = exp(↵j +  j ⇥ i),
where ↵j loosely reflects the log mean read count under the control and  j represents the jth
sgRNA eﬀect (i.e., the log diﬀerence in mean read count between the treatment and control).
The total number of genes G was set to be 10000. For genes that have eﬀects during the
screen processes under diﬀerent conditions (which are referred to as true hits), we first
generated the sgRNA eﬀects targeting gene g from a normal distribution,  j ⇠ N(µg,  2)
for j 2 Ig, g = 1, 2, . . . , G, with gene-specific mean µg and constant standard deviation
  = 0.4 (0.4 was chosen to be close to the standard deviation estimated from real data);
and then we forced all  j’s for gene g to have the same sign as µg. The vector, which
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contains diﬀerent levels of µg in our simulation, was set to be [1.5, 1, 0.5, 1, 2, 3], where
a positive number indicates that a gene’s ablation promotes cell growth while a negative
number indicates a gene is necessary for cell growth. The three levels of µg for each sign
represent the high/medium/low eﬀects of positively/negatively selected genes, respectively.
There are 50 genes simulated from each level of µg. Thus, among the 10000 genes, there
are 150 positively selected genes and 150 negatively selected genes. For those genes with no
eﬀects,  j’s were set to be 0.
Oﬀ-target eﬀects of CRISPR are often caused by unintended DNA cleavage at non-
targeting sites as a result of mismatch between DNA and sgRNA (Cho et al., 2014). If an
sgRNA is an oﬀ-target eﬀect, its read count may either decrease, increase, or remain the same
since most DNA sequences in the human genome have no known function. In our simulation,
oﬀ-target  j’s were simulated from N(0,  2) and then used to replace a certain proportion
of randomly-selected on-target sgRNAs. The oﬀ-target rate of a library can be considered
an important characteristic reflecting the quality of the library, which is determined by the
algorithm used to design the sgRNAs (Xu et al., 2015). Although several experimental
approaches exist, it is still challenging to get accurate estimates of sgRNA oﬀ-target rates
(Wu et al., 2014; Zhang et al., 2015). Reported oﬀ-target rates vary greatly in the literature
(Fu et al., 2013; Haeussler et al., 2016) and can range between 1% and 20% in most sgRNA
libraries. Thus, we tested 4 oﬀ-target proportion values: 1%, 5%, 10% and 20%, to represent
sgRNA libraries of diﬀerent quality.
Besides the library quality, the number of sgRNAs per gene is another factor that is
known to influence the screen performance dramatically. Thus, we varied the number of
sgRNAs per gene from 2 to 6 as well.
With  j’s simulated for all sgRNAs, we obtained  1j =  0j exp( j). Then we simulated
Yij from the DM distribution with  ij’s from statistical packages ’multinomRob’ (Mebane Jr
and Sekhon, 2009) and ’dirmult’ (Tvedebrink, 2010).
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1.3.2. Positive selection performance
We compared the performance of PBNPA, RSA, ScreenBEAM and MAGeCK for the
four diﬀerent oﬀ-target rates (1%, 5%, 10%, 20%), as mentioned in the simulation strategy
section, when there are 3 sgRNAs targeting each gene. A receiver operating characteristic
(ROC) curve plots the true positive rate against the false positive rate of a binary classi-
fier for diﬀerent possible cut-oﬀ points and visualizes the performance of the classifier. As
shown in Figure 1.1, PBNPA works better for positive screening than RSA, MAGeCK and
ScreenBEAM in terms of the ROC curve and area under the curve (AUC), regardless of the
oﬀ-target proportion. Also, all the algorithms show worse performance with an increasing
oﬀ-target rate except for RSA, whose AUC increases from 0.592 to 0.637. Figure 1.2 indi-
cates that PBNPA outperforms the other algorithms with varying numbers of sgRNAs per
gene from 2 to 5. As expected, the AUC of each method increases with an increasing number
of sgRNAs per gene, as more sgRNAs enable better estimation of gene eﬀects.
As we have discussed previously,  i+ controls the degree of over-dispersion. To check the
performance of the algorithms with an increased over-dispersion level, we divided every  ij
by 10 and report the results in Figures A.1 and A.2 of Appendix: the performance of nearly
all algorithms decreases compared with the low over-dispersion setting, but the performance
of PBNPA and ScreenBEAM is comparable, and it is better than RSA and MAGeCK.
1.3.3. Negative selection performance
For negative selection, PBNPA and RSA have similar AUCs and perform better than
MAGeCK and ScreenBEAM when the proportion of oﬀ-target sgRNAs is low, as shown in
Figure 1.3. When the proportion of oﬀ-target sgRNAs increases, RSA shows some advantage
over PBNPA and is robust against this increase. Figure 1.4 shows that when we fix the oﬀ-
target proportion at 10% and vary the number of sgRNAs per gene, PBNPA and RSA have
comparable performance, and they are significantly better than MAGeCK and ScreenBEAM
when the number of sgRNAs per gene is low.
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Figure 1.1. Simulation evaluation of positive selection performance. ROC curves and AUCs
are shown for diﬀerent algorithms with an increasing oﬀ target proportion while the number
of sgRNAs per gene is fixed at 3. Each curve represents the average of ROC curves for 50
simulated datasets and above.
10
Figure 1.2. Simulation evaluation of positive selection performance. ROC curves and AUCs
are shown for diﬀerent algorithms with an increasing number of sgRNAs per gene, while the
oﬀ target proportion is fixed at 10%.
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Figure 1.3. Simulation evaluation of negative selection performance. ROC curves and AUCs
are shown for diﬀerent algorithms with an increasing oﬀ target proportion, while the number
of sgRNAs per gene is fixed at 3.
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Figure 1.4. Simulation evaluation of negative selection performance. ROC curves and AUCs
are shown for diﬀerent algorithms with an increasing number of sgRNAs per gene, while the
oﬀ target proportion is fixed at 10%.
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In the setting of high over-dispersion, RSA is the best among all and PBNPA is only
second to RSA with increasing oﬀ-target proportion in the simulated datasets, as shown
in Figure A.3 (Appendix). Figure A.4 (Appendix) shows that when we fix the oﬀ-target
proportion and vary the number of sgRNAs per gene, RSA is slightly better than PBNPA,
and they are better than the other two algorithms across diﬀerent numbers of sgRNAs per
gene. Overall, for negative selection, RSA seems to be the winner; but PBNPA provides
quite close or comparable performance to RSA, which is much better than MAGeCK and
ScreenBEAM.
1.4. Comparison of recall, precision and estimation of p values
When multiple statistical tests are performed simultaneously in the analysis of a dataset,
adjustment of p values is needed. Among the four algorithms, RSA does not provide a method
to adjust for multiple comparison. We applied the Benjamini-Hochberg (BH) procedure
(Benjamini and Hochberg, 1995) to the results from RSA and obtained FDR-adjusted p
values. The other three methods use the BH procedure by default. Then we controlled FDR
at 5% and compared recall (percent of identified true hits among all true hits), precision
(percent of identified true hits among all selected genes) and F1 of the four algorithms, where
F1 is a metric that balances recall and precision and is defined as F1 = 2 ⇥ recall⇥precisionrecall+precision .
To our surprise, when FDR was controlled at 5%, neither RSA nor ScreenBEAM was able
to identify any significant genes. Actually, under most settings, all genes in the RSA results
had an adjusted p-value of 1. This suggests that RSA and ScreenBEAM cannot accurately
estimate the statistical significance of the genes. Thus, we compared the recall, precision
and F1 of PBNPA and MAGeCK. Figure 1.5 shows the recall, precision and F1 of PBNPA
and MAGeCK for diﬀerent combinations of sgRNA number per gene (2, 3, 4, 5, 6) and
oﬀ-target rates (1%, 5%, 10%, 20%) for positive screens. From the bottom panel of Figure
1.5, it is clear that under most settings, F1 of PBNPA is the same as or slightly better
than that of MAGeCK. However, the recall of PBNPA is significantly better than that
of MAGeCK, especially when the number of sgRNAs per gene is small. In the middle
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panel, MAGeCK consistently maintains very high precision across all the settings. However,
MAGeCK tends to be too conservative in identifying true hits and may show a lack of
power. Note that when the oﬀ-target rate is high (20%) with 2 sgRNAs per gene, MAGeCK
has a recall rate of less than 10%, where it cannot identify any true hits at all in some
simulated datasets. In screening experiments, after the genome-wide screening, a secondary
screening will typically be used to validate hits from the first round (Miles et al., 2016). This
highlights the importance of the recall rate: those false positives are likely to be removed in
the secondary screening, while those false negatives can be crucial genes that will be missed
permanently. Nearly the same pattern can be observed for negative screens, as shown in
Figure A.5 (Appendix). Thus, PBNPA provides the most accurate estimation of adjusted p
values among the four algorithms and also oﬀers optimal recall rates.
1.4.1. Handling replicates
The comparisons we have discussed above are based on simulated data with no replicates.
For low-quality screens, replicates are typically used to increase the power of identification.
To handle screens with replicates, we propose to use Fisher’s method to combine p values,
as mentioned in the Methods section, followed by FDR adjustment. We simulated replicate
datasets with parameters of the DM distribution set as  ij5 , which has higher over-dispersion
than the DM distribution with  ij and so may represent data of low quality. We evaluated 3
simulated replicates independently. Among the 150 positively selected genes, the analysis of
individual replicates gives the following results (i.e., number of true hits identified/number
of genes identified by PBNPA) with FDR controlled at 5%: 6/7, 9/11, and 8/9, respectively.
After combining p values for the first two replicates, the result is 72/86. After combining
p values for all three replicates, the result is 96/111. It is evident that PBNPA shows
dramatically improved performance when even a small number of replicates are present.
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Figure 1.5. Simulation evaluation of positive selection performance based on recall, precision
and F1 for diﬀerent combinations of sgRNA number per gene (2~6) and oﬀ target ratio. Each
bar represents the average of 50 simulated datasets and the standard error is indicated on
the bar.
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1.5. Real data applications
1.5.1. Consistency between replicates
Although the performance of various algorithms usually does not diﬀer greatly in simula-
tion studies, they tend to give quite diﬀerent inferences on real data. This can be due to the
fact that a simulation is not an exact reproduction of the complex data generation process
in the real world. This phenomenon is also observed in algorithms analyzing CRISPR data
(Diaz et al., 2015). From the simulation study, we have found that PBNPA and MAGeCK
are handy to use and give better overall performance than the other two algorithms. Thus,
we used datasets from two recently published articles to evaluate the consistency between
these two algorithms as well as the consistency of the same algorithm on diﬀerent replicates
from the same experiment, since a good algorithm should give highly similar results on repli-
cates of the same experiment. The KBM7 dataset is from a study with two replicates and 10
sgRNAs per gene, which aims to identify essential genes in the human genome to reveal genes
that are oncogenic drivers or lineage specifiers (Wang et al., 2015). As shown in the upper
panel of Figure 1.6, the identified hits are highly overlapped between the two algorithms
for the same replicate, as well as between the two replicates with the same algorithm. This
indicates both algorithms perform well on this dataset with high consistency. The Toxo-
plasma dataset is from a study with four replicates, which aims to identify essential genes of
parasites for infection of human fibroblasts (Sidik et al., 2016). The library was designed to
target more than 8000 protein coding genes in T. gondii with 10 sgRNAs per gene. For this
dataset, the number of consistently identified genes for PBNPA is significantly higher than
that identified by MAGeCK among the 4 replicates, as is shown in the middle and bottom
panels of Figure 1.6. For PBNPA, there are 19 genes consistently identified in all four repli-
cates and 80 genes consistently identified in at least three replicates. However, for MAGeCK
there is no gene identified in all four replicates and only 11 genes consistently identified in
at least three replicates. This is strong evidence that PBNPA has superior consistency and
better FDR control than MAGeCK.
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Figure 1.6. Comparing consistency of MAGeCK and PBNPA on replicates using real data.
Upper panel: overlap of PBNPA and MAGeCK results on replicates 1 and 2 of the KBM7
dataset. Middle panel: overlap of PBNPA results on the four replicates of Toxoplasma.
Bottom panel: overlap of MAGeCK results on the four replicates of Toxoplasma.
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1.5.2. FDR control
Control of FDR is also studied by comparing control vs control or treatment vs treatment
read counts between replicates, as no genes should be identified in this comparison. For
the KBM7 dataset, we analyzed controls vs controls or treatment vs treatment with the
two algorithms and found that PBNPA has fewer falsely identified genes compared with
MAGeCK, as shown in Table 1.1. For the Toxoplasma dataset, the results also indicated
PBNPA had fewer falsely identified genes than MAGeCK which is showed in Table 1.1.
Dataset KBM7 Toxoplasma
Selection
direction
Algorithm Ctrl1 vs
ctrl2
Trt1 vs
trt2
Ctrl1 vs
ctrl2
Ctrl1 vs
ctrl3
Trt1 vs
trt2
Trt1 vs
trt3
Positive
MAGeCK 50 18 0 1 0 1
PBNPA 38 10 0 1 1 0
Negative
MAGeCK 0 3 4 2 6 28
PBNPA 0 6 0 2 0 0
Table 1.1. Comparison of FDR control between MAGeCK and PBNPA
1.6. Discussion
The similarities and diﬀerences in performance of the two algorithms, MAGeCK and
PBNPA, on the two real datasets can be explained below. In the KBM7 dataset, each
gene is targeted by 10 sgRNAs. From our simulation study, 10 sgRNAs per gene should be
suﬃcient to give reliable inference on the hits. Thus, these two algorithms give highly similar
results. For the Toxoplasma dataset, although there are 10 sgRNAs designed for each gene,
the algorithm used to design sgRNAs is optimized for human genes not for Toxoplasma,
which, we conjecture, would deteriorate the eﬃciency of sgRNAs in the screen. In addition,
the screening pipeline for Toxoplasma diﬀers from that for cultured human cells, which may
induce unknown variability in the data. Based on the above rationale, we conclude that
PBNPA is more robust to data variability than MAGeCK. We also note that the other two
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methods (RSA and ScreenBEAM) did not perform well on these real data, which agrees with
our findings from simulation. In particular, RSA showed poor performance in controlling
FDR; for example, in the KBM7 dataset, when we compared ctrl1 vs. ctrl2, RSA claimed
more than 90% of the genes are significant when controlling FDR at 5% for positive selection.
This is also consistent with an observation in the MAGeCK paper (Li et al., 2014) that RSA
has a high FDR.
While researchers typically use gene-specific null distributions in their permutation pro-
cedures, we employed a common null probability distribution for all genes in PBNPA. We
find that this gives similar or even slightly better performance than using gene-specific null
distributions. However, building a common null distribution for all genes substantially saves
computation time over building gene specific null distributions. For example: if there are
10,000 genes and we permute 10 times, we can get a common null distribution for all genes
based on 10000⇥ 10=100,000 replicates; but we need to permute 100,000 times if we want
an individual null distribution for each gene based on the same number of replicates. Here,
using a common null distribution saves 10,000 times as much computation time as using
gene-specific null distributions.
Although our algorithm is designed to analyze CRISPR data, it can also be applied
to analyze genetic screens implemented with siRNAs or shRNAs and drug screens, which
all generate data with structures similar to those in CRISPR screens. The idea of doing
permutation twice, with significant genes from the first round removed to get a more accurate
null distribution, could be used by other studies where p values are mainly generated from
a permutation process. We note that there are supervised methods of analyzing CRISPR
data, which need previous knowledge to estimate the background noise in the platform and
variability in the data (Hart and Moﬀat, 2016). Such methods are suitable in situations
when reliable previous screening results are available.
To the best of our knowledge, our paper is the first study to compare the performance
of several algorithms with simulated datasets. With the known ground truth, we showed
the overall superiority of our PBNPA algorithm compared to several existing methods in
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analyzing CRISPR data, which is also verified by the real data studies. The behaviors of
each algorithm are revealed from simulation studies, which could help researchers select the
most appropriate algorithm to analyze CRISPR data.
Although there are many existing algorithms available for analyzing CRISPR data, re-
searchers are particularly interested in new algorithms that can give consistent and reliable
results with a small number of sgRNAs per gene and a low sequencing depth and that are
not sensitive to platforms, which will facilitate genome-scale screens while lowering the cost.
Our PBNPA algorithm is a step toward achieving this goal.
1.7. R package
We created an R package to implement PBNPA. This package is available at at CRAN:
https://cran.r-project.org/web/packages/PBNPA/index.html.
The main function in the package named ’PBNPA’. This function uses the raw read
count data for CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) screens
and conducts statistical analysis for permutation based non-parametric analysis of CRISPR
screen data. This function can also be used to analyze data from other types of functional
genomics screens such as siRNA screen or shRNA screen. Drug screens or microarray ex-
pression data, if they have structures similar to what this algorithm is designed for, can also
be analyzed with this function as the algorithm has no specific distributional assumptions
for the data and p-values are calculated from a permutation based procedure. It can han-
dle data with multiple replicates. After executing the function, a list of 5 elements will be
returned. The first element is pos.gene, which is the index of genes identified as hits for
positive screen by controlling FDR at the selected level; the second element is pos.number,
which is the number of genes identified as hits for positive screening; The third element is
neg.gene, which is the index of genes identified as hits for negative screen by controlling
FDR at the selected level; the fourth element is neg.number, which is the number of genes
identified as hits for negative screening; the fifth element is a dataframe which contains un-
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adjusted p-values and FDR adjusted p-values for all the genes (for both negative selection
and positive selection).
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Chapter 2
RCRNORM: AN INTEGRATED SYSTEM OF RANDOM-COEFFICIENT
HIERARCHICAL REGRESSION MODELS FOR NORMALIZING NANOSTRING
NCOUNTER DATA FROM FFPE SAMPLES
2.1. Introduction
Formalin-fixed paraﬃn-embedded (FFPE) tissue samples are usually collected for diag-
nostic purposes in clinical routines (Lüder Ripoli et al., 2016). Unlike freshly frozen (FF)
tissue samples that must be frozen instantly after collection and then stored in freezers,
FFPE samples can be stored at room temperature and kept for a long time. Due to the
ease of handling and inexpensive storage (Perlmutter et al., 2004), numerous FFPE tissue
samples have been deposited into tissue banks and pathology laboratories around the world,
and are readily available (Lüder Ripoli et al., 2016; Reis et al., 2011). Such samples are
often accompanied by well documented patient information, disease status and long-term
clinical follow up information. Further, there exist vast archives of specimens from which
only FFPE, but no FF, samples can be obtained (e.g., specimens of a deceased patient).
Thus, the ubiquity of FFPE samples has made them a highly valuable resource in biomedi-
cal studies. In particular, FFPE samples have great potential for biomarker discovery, which
can be critical for disease diagnosis, prognosis and treatment plan selection (Ludwig and
Weinstein, 2005; Rosenfeld et al., 2008; Xie et al., 2011).
Despite advantages of FFPE samples, the formalin fixation process breaks RNA into small
pieces with an average size of ⇠ 200nt and irreversible methylene crosslinks between RNAs
and proteins may form that aﬀect enzyme based downstream reactions (Masuda et al., 1999).
The low quality of RNA from FFPE samples hinders reproducibility and sensitivity of assays
for quantitatively measuring gene expression levels via microarray experiments or real time
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polymerase chain reaction (qPCR) which involves enzyme-mediated reverse transcription
from mRNA to cDNA (Von Ahlfen et al., 2007). Thus, in order to exploit the vast collection
of FFPE samples, robust assays are needed to enable and improve expression profiling in
these samples.
In recent years, several methods/platforms have been developed for gene expression pro-
filing in FFPE samples either at the genome-wide scale or for a subset of genes. April et
al. developed a whole genome cDNA-mediated annealing, extension, selection, and ligation
(WG-DASL) assay to perform gene expression profiling in FFPE samples (April et al., 2009).
Iddawela et al. reported that WG-DASL assays could reliably probe gene expression levels in
breast cancer FFPE samples (Iddawela et al., 2016). Abdueva et al. showed that Aﬀymetrix
microarrays could be used to probe gene expression signatures and perform diﬀerential ex-
pression analysis with FFPE samples and obtained results comparable to those from unfixed
tissues (Abdueva et al., 2010). Thompson et al. developed the HTG EdgeSeq chemistry
platform that uses RNA extraction-free nuclease protection assay (qNPA), followed by the
quantification of RNA molecules by next generation sequencing techniques such as RNA-seq,
to profile microRNA and RNA in FFPE samples (Thompson et al., 2014).
Unlike whole genome expression profiling above, Paluch et al. developed targeted RNAseq
that can selectively examine the abundance of immune related genes on archival FFPE sam-
ples (Paluch et al., 2017). Usually, platforms for measuring expression levels of a subset
of genes only are called medium-throughput platforms. Compared to the high-throughput
(genome-wide) platforms, they often have better technical reproducibility and are more read-
ily to use in clinical settings. For medium-throughput platforms, besides the probes for
detecting genes of interest, there are usually probes designed for internal control, for exam-
ple, negative controls, positive controls and housekeeping genes. Negative controls target
no known sequence and should have zero count ideally; positive controls added to the reac-
tion system have known amounts of RNA targets; and housekeeping genes maintain basic
cell functions, with expression levels that minimally fluctuate across diﬀerent individuals
compared with other genes (Waggott et al., 2012). These internal controls can provide infor-
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mation for adjusting for unwanted biological and technical eﬀects that can mask the signal
of interest.
Among the medium-throughput platforms, the NanoString nCounter is the most popular
(Geiss et al., 2008). It is highly multiplexed – it can eﬀectively detect up to 800 genes in a
single tube in one run, which bridges the gap between genome-wide expression profiling by
microarray or RNAseq and targeted profiling by qPCR (Kulkarni, 2011). More importantly,
the nCounter platform is a Clinical Laboratory Improvement Amendments (CLIA) certifiable
assay (for Medicare & Medicaid Services et al., 2005), which could be translated into clinical
settings.
Due to its importance in medium-throughput profiling, several analysis methods includ-
ing NanoStringNorm, NAPPA and NanoStringDiﬀ have been developed for the NanoString
nCounter platform to normalize and extract gene expression levels from diﬀerent samples.
These algorithms are mainly focused on removing noise from each of the following three
sources with the use of one specific type of internal controls: (1) lane-by-lane noise, which
results from variation in experimental conditions (such as humidity, temperature, etc.) be-
tween reaction systems, is estimated and removed using information from positive controls;
(2) background noise, introduced by non-specific binding of the probes, is estimated and re-
moved using negative controls; and (3) variation in sample loading amounts or diﬀerence in
RNA degradation levels is evaluated using housekeeping genes (Waggott et al., 2012; Wang
et al., 2016; Harbron and Wappett, 2015).
To be specific, NanoStringNorm is an R package that implements a normalization protocol
recommended by the manufacturer’s guideline (Waggott et al., 2012). First, the lane-by-lane
variation is removed by scaling the samples with a factor that makes summary statistics of
positive control counts (e.g., mean, median, or geometric mean) equal across samples. Then
background correction is performed by subtracting the read count with a statistic represent-
ing the background noise, for example, the mean or maximum count of negative controls.
Finally, the loading variation is adjusted by a factor calculated from housekeeping genes in
the same way as in the first step. It is obvious that NanoStringNorm performs normalization
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in an ad hoc way without any rigorous statistical model involved. NAPPA is perhaps the
most commonly used algorithm by researchers to normalize NanoString data (Harbron and
Wappett, 2015), to the best of our knowledge. This algorithm adjusts the background noise
with a truncated Poisson distribution and corrects the loading variation by fitting a sig-
moidal curve while normalizing the lane-by-lane variation similarly as in NanoStringNorm.
NanoStringDiﬀ is originally designed for identifying diﬀerentially expressed genes based on
the NanoString nCounter platform, but can be easily adapted for the purpose of normaliza-
tion (Wang et al., 2016). NanoStringDiﬀ fits a generalized linear model to the data, from
which three factors are extracted from positive controls, negative controls and housekeeping
genes to adjust for lane-by-lane variation, background noise and variation in the amount of
input sample, respectively.
Although the three methods are designed for or can be used to normalize NanoString
nCounter data, no meticulous research has been conducted to study the characteristics of
this type of data from FFPE samples; and no simulation studies were carried out to evaluate
their performance in normalizing such FFPE data. In addition, information provided by
diﬀerent types of internal controls is intermingled. For example, although positive controls
are designed to measure the noise from varying experimental conditions, read counts from
negative controls can also provide useful information about this type of noise. The current
normalization methods ignore this fact and cannot make the best use of data. In addition,
all current algorithms use housekeeping genes by assuming that their expression levels are
constant between diﬀerent samples or individuals. But this may be fallacious – biologists
generally define housekeeping genes as those that do not vary much between diﬀerent tissues
of an individual, but they have not evaluated the stability of their expression levels from
diﬀerent individuals (Eisenberg and Levanon, 2013). Thus, advanced statistical modeling
based on an integrated understanding of the nCounter system without restrictive model
assumptions is needed to boost its application in clinical and academic research.
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We begin by exploring key features of the NanoString nCounter data from FFPE samples
in Section 2.2. In Section 2.2.3, we construct an integrated system of random-coeﬃcient
hierarchical regression models for modeling read counts from the diﬀerent types of probes in
the nCounter system. Section 2.3 describes our computational strategy based on a Bayesian
approach. We label the proposed method by RCRnorm, where “RCR” stands for random-
coeﬃcient hierarchical regression and “norm” stands for normalization. Section 2.4 presents a
formal simulation study, conducted to evaluate the performance of RCRnorm in comparison
with the three existing methods (i.e., NanoStringNorm, NAPPA and NanoStringDiﬀ), as well
as examine its robustness to deviations from key model assumptions. Section 2.5 provides
real data applications to illustrate the proposed Bayesian approach. Section 2.6 concludes
the paper with a brief summary and some in-depth discussion.
2.2. Motivating example
2.2.1. Data description
The data that motivate our research are from a published study (Xie et al., 2017), which
aims to validate a 12-gene signature for predicting adjuvant chemotherapy (ACT) response
in lung cancer. A gene signature is a subset of genes, selected from all human genes (more
than 20,000), which can be used for diagnosis or prognosis of diseases such as cancer (Ziober
et al., 2006; Chen et al., 2007). Typically, a gene signature is identified via variable/model
selection techniques, with each gene’s expression measurement corresponding to a variable.
The 12-gene signature was developed from FF samples to predict, among lung cancer
patients, who would benefit from ACT so that patients that are unlikely to benefit from ACT
can avoid adverse eﬀects of unnecessary treatment (Tang et al., 2013). As mentioned in the
introduction, FFPE samples are widespread. FF samples, however, are not readily available
for clinical applications, due to reasons including (i) easy contamination by pathogenic germs,
(ii) rapid deterioration in room temperature, and (iii) much higher storage cost for frozen
specimens than room temperature specimens (Stefan et al., 2010). Thus, it is important
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to validate the performance of the signature on FFPE samples so that a clinical applicable
assay can be developed based on the nCounter platform (Xie et al., 2017).
The dataset used by Xie et al. (Xie et al., 2017) contains gene expression levels measured
by the nCounter platform on paired FF and FFPE samples from 30 patients. The goal
in their study is to verify that each gene’s expression levels of the 30 patients from FFPE
samples are well correlated with those from paired FF samples so that the statistical model
based on the 12-gene signature derived from FF samples can be applied to FFPE samples
as well. Although this signature only contains 12 genes, 87 genes in total were measured in
the dataset.
Table B.1 in appendix shows the data structure derived by combining raw data files for
diﬀerent patient samples, where each row represents a probe, and each column except for
the first two represents a sample. The 1st column labeled “CodeClass” indicates the probe
type: negative controls, positive controls, housekeeping and regular genes. The 2nd column
contains unique probe names. Generally, there are six positive controls (i.e., P = 6) in
the code set, but the number of negative controls N and the number of housekeeping genes
H can vary. The name of each negative or positive control contains a pair of parentheses,
within which there is a number indicating the concentration amount of RNA added to the
system that is targeted by that control. For the six positive controls, the RNA amount is
0.125, 0.5, 2, 8, 32, 128 fM, respectively, while for all negative controls, it is zero since there
is no known RNA transcript that can be targeted by the probes. All the other columns in
Table B.1 contain (transformed) read counts from individual samples. As will be detailed
in Section 2.2.3, each (transformed) count is denoted by Y , with a superscript representing
the code-class aﬃliation, the 1st subscript denoting the patient ID and the 2nd subscript
denoting the probe ID in that code class.
In the study (Xie et al., 2017), the (paired) data involve two tables in the form of
Table B.1, one for FF samples and the other for FFPE samples from the same set of patients.
There are 8 negative controls, 7 housekeeping genes and 87 regular genes besides 6 positive
controls in the data.
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Data generated by the nCounter system have to be normalized, to account for sample
preparation variation, sample content variation, and background noise, etc., before they can
be used to quantify gene expression and conduct any downstream statistical analysis. Here,
the availability of data from FFPE samples would allow us to explore major characteristics
of such data and examine key assumptions/hypotheses about the mean structure of the data,
when developing a new normalization method that aims to improve existing ones. Meanwhile,
the availability of data from paired FF samples would enable us to quantitatively assess and
compare the performance of any normalization methods developed for the nCounter system.
Due to the lack of ground truth, it is generally diﬃcult to compare the performance of
diﬀerent normalization methods on real data. Nevertheless, the data from FF samples,
once available, can be used to provide a surrogate of the truth. This is because FF tissues
are known to maintain RNA very well (much lower degradation of RNA and no methylene
crosslink between RNA and proteins) and thus are considered as a gold standard for most
molecular assays (Solassol et al., 2011).
2.2.2. Exploratory analysis
To ensure that data resulting from an nCounter gene expression experiment is of adequate
quality to be used in subsequent analysis, it is necessary to apply quality control procedures
according to the NanoString guidelines. Among the 30 patients’ FFPE samples with 87
regular genes, two patients and four genes were removed for their compromised data quality
because they have mean read counts lower than the maximum count of negative controls.
An interesting fact is that the two samples discarded are the oldest among the 30 FFPE
samples and were collected before the year of 2000. This supports the notion that storage
time is a key factor that influences RNA quality from FFPE samples (Von Ahlfen et al.,
2007).
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Figure B.1 in appendix plots raw read counts of six positive control probes vs. patient
index for FFPE samples. It shows that on the un-transformed scale, the high count probes
have high variance. This is a general property of count data generated from sampling dis-
tributions, whose variance typically increases with the mean. Thus, we apply the commonly
used log transformation to the raw counts; and to avoid  1 arising from zero counts, we
add 1 to the observed counts before applying the logarithm.
The empirical distributions of the log10 transformed gene read count of FFPE vs FF
samples are showed in Figure 2.1(a) and (b), respectively, in which each (density) curve
corresponds to a patient sample and is plotted using log read counts of housekeeping and
regular genes. It is obvious that the locations of the distributions of FFPE samples vary
more dramatically than those of FF samples. This indicates the existence of heterogeneity in
RNA degradation and fragmentation levels among the 28 FFPE tissue samples, contributing
to individual sample eﬀects in transcript abundance. This should be modeled, whenever
possible, to enable comparison of gene expression levels between patients after removal of
such technical artifacts.
Figure 2.1(c) plots log read counts of six positive control probes vs. patient index for
FFPE samples. Compared with Figure B.1, we can see that the log transformation greatly
stabilizes the count variance. Another noticeable observation is that the zig-zag patterns for
the six probes are so similar, strongly indicating the existence of the lane eﬀects.
Given a sample i, one would expect that the log transformed read count (say Yij) of any
probe j has a monotonically increasing relationship with the corresponding RNA amount
(say Rij). Using positive controls whose RNA amounts are known and fixed over all i (i.e.,
Rij ⌘ Rj and Rjs are known), we can compute the correlation between Rij and Yij and
that between Xij and Yij for each patient i, where Xij ⌘ logRij. Figure 2.1(d) shows two
boxplots based on FFPE samples, one for the 28 correlations using log RNA amounts and
the other for those using original RNA amounts. We can see that the correlations using
log RNA amounts are much higher, with values very close to 1. Thus, a linear relationship
between the log RNA amount Xij and log read count Yij seems to capture the underlying
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Figure 2.1. Exploratory analysis of lung cancer data from xie et al. (Xie et al., 2017). Panels (a)
and (b) show empirical distributions of log read counts based on housekeeping and regular genes
for the 28 FFPE and FF samples, respectively. For FFPE samples, panel (c) plots log read counts
of six positive controls (with diﬀerent known RNA concentration amounts) vs. patient index; (d)
compares the boxplot of correlations between log RNA amount and log read count with the boxplot
of correlations between RNA amount and log read count; (e) shows empirical densities of patient-
wise intercepts and slopes, and (f) overlays the 28 patient-wise fitted lines of log read count vs
log RNA amount, all estimated using data from positive controls; and panel (g) shows boxplots
of residuals for the eight negative and six positive controls from fitting the linear trend (2.1) per
patient, where each boxplot contains residuals from 28 patients for a control probe.
31
pattern well. More precisely, for each sample i, this can be described by
E(Yij|Xij = x, ai, bi) = ai + bix, (2.1)
where ai and bi are sample-specific regression coeﬃcients.
Figure 2.1(e) shows the empirical densities of ais and bis; and 2.1(f) shows the linear
trend (2.1) for each patient, all estimated using FFPE data from positive controls. The
straight lines in Figure 2.1(f) are similar but apparently do not overlap. This suggests that
the simplifying assumption ai ⌘ a (or bi ⌘ b) is not appropriate; but ais (or bis) share some
commonality and so may come from the same distribution. From Figure 2.1(e), we can see
that the two distributions are well apart with diﬀerent spreads; and the Shapiro-Wilk test
(Shapiro and Wilk, 1965) suggests no gross departure from normality at the significance level
0.05 for either distribution. Thus, it is plausible to assume that ais and bis are random and
follow two separate normal distributions.
For every housekeeping or regular gene, the RNA amount Rij reflects gene j’s expression
abundance in sample i, whose value is unknown. But for negative controls, Rij ⌘ 0 so that
Xij =  1, which is ill defined. To solve this issue, we add a small positive number   so
that Xij = log   instead and (2.1) holds for negative controls as well. Both   and Rijs are
estimable. The intuition is that with the information from positive controls, we can pin
down (ai, bi) for each sample so that with observed counts from negative controls, we can
estimate  , and with observed counts from housekeeping or regular genes, we can estimate
Rijs.
We use
P
i=1
P
j2J (Yij   aˆi)/bˆi to obtain a rough estimate of log   for FFPE samples,
where J   denotes the index set of negative controls, and aˆi and bˆi are estimated using data
from positive controls as before. We then compute the residuals, i.e. deviations from the
linear pattern (2.1), for each positive and negative control, and their boxplots are shown
in Figure 2.1(g). Two interesting observations can be made here, which will be useful for
the model construction in Section 2.2.3. First, negative controls tend to have much larger
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deviations than positive controls; and their distributions tend to have much larger variability
(hence wider spreads). Second, for each individual probe, the residuals are not randomly dis-
tributed around zero: all the boxplots for positive controls are entirely above/below zero, and
most boxplots for negative controls have 75% residuals or more above/below zero, indicating
residuals are clustered by probes.
2.2.3. Proposed data model based on RCR
Let i index (FFPE) patient samples, p index positive controls, n index negative controls,
h index housekeeping genes, and r index regular genes, for i = 1, . . . , I, p = 1, . . . , P ,
n = 1, . . . , N , h = 1, . . . , H, and r = 1, . . . , R, where I is the number of patients, P , N ,
H and R are the (prespecified) number of positive controls, negative controls, housekeeping
genes and regular genes in the NanoString nCounter platform, respectively.
Motivated by the analysis in Section 2.2, we set up a system of (hierarchical) linear
regression models with random coeﬃcients for the four diﬀerent types of probes, in which the
general linear relationship between the observed log read count and log RNA amount (either
known or unknown) is assumed regardless of the probe type; and except for the observed log
read counts, all the random components of the system are assumed to be independent. We
begin with the model for the positive control class, given below:
Y +ip = ai + biX
+
p + d
+
p + e
+
ip, (2.2)
where Y +ip is the logarithm of read count plus 1 of the pth positive control from the ith
sample, X+p represents the logarithm of the known RNA input amount (unit: fM) in the
reaction system, and the superscript ’+’ indicates the membership of the positive control
class. The ai and bi are the sample-specific random intercept and slope which may reflect
the lane-by-lane variation. According to Figure 2.1(e)-(f), we may assume ais and bis be
independent and identically distributed normal variables, respectively: ai
iid⇠ N(µa,  2a) and
bi
iid⇠ N(µb,  2b ). Further, d+p represents the probe-specific systematic deviation from the linear
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pattern (2.1) (see Figure 2.1(g)) and we assume d+p ⇠ N(0,  2d). Finally, e+ip ⇠ N(0,  2e) is the
random error term, which reflects the remaining variability of the log observed count after
taking into account the linear trend and the probe-specific deviation.
For the negative control class, the model is given by
Y  in = ai + bic+ d
 
n + e
 
in, (2.3)
where Y  in is the logarithm of read count plus 1 of the nth negative control from the ith
sample, c ⌘ log   is an unknown constant, the superscript ’-’ indicates the membership
of the negative control class, and the other terms are defined similarly as in (2.2). As
shown in Figure 2.1(g), the distributions of deviations (from the main linear pattern) for
positive controls are very diﬀerent from those for negative controls: from the centers (i.e.,
middle horizontal bars) of the boxplots, we can see d n s vary more than d+p s; and from the
widths of the boxplots, we can see e ins vary much more than e
+
ips. Thus, we have to assume
d n ⇠ N(0,  2d ) and e in ⇠ N(0,  2e ), where the data suggest that  2d  >  2d and  2e  >  2e .
For the housekeeping gene class, the model is given by
Y ⇤ih = ai + biX
⇤
ih + d
⇤
h + e
⇤
ih, (2.4)
where X⇤ih is the unknown log RNA amount of the hth housekeeping gene from sample i, the
superscript ’*’ indicates the membership of the housekeeping gene class, and the other terms
are defined similarly as before. Unlike positive or negative controls, X⇤ih in (2.4) is random
by nature rather than being constant, which can be decomposed into a random term ⇤ih and
a fixed term  i, i.e., X⇤ih =  i + ⇤ih. Here,  i is a constant that reflects the individual eﬀect
of sample i in transcript abundance (e.g., patient-to-patient variation, variation in RNA
degradation and fragmentation levels of FFPE tissues, variation in the amount of input
sample material, etc.), satisfying
PI
i=1  i = 0; and ⇤ih ⇠ N( ⇤h,  2⇤) reflecting the remaining
expression abundance after adjusting for the sample eﬀect. Note that E(X¯⇤.h) =  ⇤h, where
X¯⇤.h =
PI
i=1X
⇤
ih/I and  ⇤h is the gene-specific mean of the log RNA amount. Here, individual
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sample eﬀects  is and gene eﬀects  ⇤hs are both modeled as fixed eﬀects instead of random
eﬀects. This is because for a specific sample, we are interested in recovering ⇤ih from X⇤ih,
rather than inferring the marginal distributions of  is and  ⇤hs.
For the regular gene class, the RNA amounts in diﬀerent samples are unknown, too. So
the model is set to be the same as that for the housekeeping gene class, but with a diﬀerence
probe index r and no superscript (for notational brevity):
Yir = ai + biXir + dr + eir, (2.5)
where Xir =  i + ir is the unknown log RNA amount of the rth regular gene from sample
i, and the definitions of ir, dr and eir are self-evident. Correspondingly, we assume ir ⇠
N( r,  2). Note that two separate variances,  2⇤ and  2, are needed for the housekeeping
and regular genes, respectively. This is because expression levels of housekeeping genes are
known to be more stable across samples, and so one would expect  2⇤ <  2.
In the reaction system of the nCounter platform, negative controls have no known target
and all detected binding signals should be from non-specific binding while positive controls,
housekeeping and regular genes all have known targets, and so their working mechanisms may
be similar. Thus, we assume d+p , d⇤h, dr ⇠ N(0,  2d) and e+ip, e⇤ih, eir ⇠ N(0,  2e). We comment
that for the housekeeping and regular genes, (2.4) and (2.5) are both hierarchical: the bottom
layer involves a linear regression model with random coeﬃcients, and the second layer (for the
unknown log RNA amount) involves a two-way ANOVA model, where one factor represents
the sample-specific eﬀect  i and the other factor represents the gene-specific eﬀect that are
related to  ⇤h or  r. In addition, for all the four classes, since gene-specific deviations from
the main linear trend (2.1) are allowed through d+p , d n , d⇤h and dr, the log read counts of the
same gene from diﬀerent samples (e.g., Yir and Yi0r) are correlated; meanwhile, the log read
counts of the diﬀerent genes from the same patient (e.g., Yir and Yir0) are correlated, too, as
they share the same random intercept ai and slope bi.
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2.3. Bayesian approach
2.3.1. Full probability model
Based on the system of equations (2.2)-(2.5), the parameters of our data model include
µa,  2a, µb,  2b ,  2d,  2e ,  2d ,  2e ,{ i}I 1i=1 ,{ ⇤h}Hh=1,  2⇤, { r}Rr=1,  2, and c, among which µa,
µb, c,  is,  rs, and  ⇤hs are location parameters, and all the others are variance parameters.
We assume all these parameters are a priori independent. Let Y denote all the log
read count data observed; and let ⇥ denote the collection of all latent random variables
involved, including {ai}Ii=1, {bi}Ii=1, {d+p }Pp=1, {d n }Nn=1, {d⇤h}Hh=1, {dr}Rr=1, {{⇤ih}Hh=1}Ii=1 and
{{ir}Rr=1}Ii=1, and all model parameters. Further, we use N(x|µ,  2) to denote a normal
distribution with mean µ and variance  2, and ⇡(·) to denote a general prior distribution.
Then the full probability model is given by
p(Y ,⇥) /
IY
i=1
(
PY
p=1
N(Y +ip |ai + biX+p + d+p ,  2e) ·
NY
n=1
N(Y  in |ai + bic+ d n ,  2e )
·
HY
h=1
N(Y ⇤ih|ai + bi( i + ⇤ih) + d⇤h,  2e) ·
RY
r=1
N(Yir|ai + bi( i + ir) + dr,  2e)
·
HY
h=1
N(⇤ih| ⇤h,  2⇤)) ·
RY
r=1
N(ir| r,  2) ·N(ai|µa,  2a) ·N(bi|µb,  2b )·
)
·
PY
p=1
N(d+p |0,  2d) ·
NY
n=1
N(d n |0,  2d ) ·
HY
h=1
N(d⇤h|0,  2d) ·
RY
r=1
N(dr|0,  2d)
· ⇡(µa) · ⇡(µb) · ⇡(c) ·
IY
i=1
⇡( i) ·
HY
h=1
⇡( ⇤h) ·
RY
r=1
⇡( r)
· ⇡( 2a) · ⇡( 2b ) · ⇡( 2d) · ⇡( 2e) · ⇡( 2d ) · ⇡( 2e ) · ⇡( 2⇤) · ⇡( 2),
where the first four lines represent the joint likelihood of the observed data and latent random
variables, the fifth line represents prior distributions of the location parameters, and the last
line represents prior distributions of the variance parameters.
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2.3.2. Prior specification
For each variance parameter involved, we specify an inverse gamma prior distribution
IG(u, v), where u and v are small positive numbers to make the prior very vague and diﬀuse
(e.g., u = v = 0.01). The purpose of doing so is to let the data speak for itself when sampling
the variances from the joint posterior distribution.
For µa and µb (mean of random intercepts ais and mean of random slopes bis), we consider
normal priors: µa ⇠ N(µˆa,m⇥ se(µˆa)) and µb ⇠ N(µˆb,m⇥ se(µˆb)). Here, m is a prespecified
constant (e.g., 3, 5) to make the prior much more diﬀuse than what data suggest; µˆa and µˆb
are crude estimates of µa and µb; and se(µˆa) and se(µˆb) are their standard errors. We simply
set µˆa =
PI
i=1 aˆi/I and µˆb =
PI
i=1 bˆi/I, where aˆi and bˆi are the (least square) estimated
intercept and slope, respectively, from fitting Y +ip vs. X+p for each patient i; and the standard
errors can be estimated using jackknife resampling that removes two patient samples at a
time (Efron and Stein, 1981).
For any other location parameter (say ✓), we use a noninformative uniform distribution,
✓ ⇠Uniform (L✓, U✓), which should provide a suﬃciently wide coverage for all plausible values
of ✓ suggested by data. For the added small value   associated with negative controls, we
consider the range (10 6, 10 1) so that c ⇠ Uniform( 6, 1) is specified a priori. For the
gene-specific mean of the log RNA amount  r, the lower and upper bounds can be specified
by mean(Xˆr) ± m ⇥ sd(Xˆr), where Xˆr = (Xˆ1r, · · · , XˆIr), and Xˆir is a crude estimate of
the log RNA amount of regular gene r from sample i, e.g. Xˆir = (Yir   aˆi)/bˆi. The bounds
for  ⇤h can be specified similarly using Xˆ⇤ih = (Y ⇤ih   aˆi)/bˆi for each housekeeping gene. Note
that an alternative method to specify a conservative prior range for any of  rs and  ⇤hs is to
use the maximum and minimum statistics, especially when we anticipate that the posterior
distribution can be skewed. For example, the lower and upper bounds of  r can be specified
by min{Xˆr}    r and be max{Xˆr} +  r where  r is a prespecified constant that leaves
some extra safe room for either bound (e.g., setting  r = sd(Xˆr)).
Finally, for the sample eﬀect  i, the lower and upper bounds can be specified by  ˆi ±
m ⇥ se( ˆi). Here, the rough estimate  ˆi and its standard error can be easily obtained
37
using regular genes by running a standard two-way ANOVA model on Xˆ ⌘ (Xˆr)Rr=1 with
the constraint that the sum of sample-specific eﬀects and the sum of gene-specific eﬀects
are zero. Alternatively, they can be estimated nonparametrically:  ˆi =
¯ˆXi.   ¯ˆX.., where
¯ˆXi. =
1
R
PR
r=1 Xˆir and
¯ˆX.. =
1
IR
PI
i=1
PR
r=1 Xˆir; and se( ˆi) can be roughly estimated using
jackknife resampling that removes two housekeeping genes at a time.
2.3.3. Posterior computation and Bayesian inference
We use Markov Chain Monte Carlo (MCMC) to draw random samples from the joint
posterior distribution p(⇥|Y ), which is proportional to p(Y ,⇥). Standard diagnostic tech-
niques (Gelman et al., 2014) are used to detect the convergence. One advantage of the
proposed method is that the posterior conditionals, as detailed in appendix B.2, are all
known distributions, from each of which direct sampling can be done. This property al-
lows us to design an eﬃcient Gibbs sampler, in which all the involved quantities are drawn
sequentially and generated readily without using any built-in sampling algorithm (such as
Metropolis–Hastings and Acceptance/Rejection algorithms) that can greatly slow down the
computation.
For the purpose of gene expression normalization, we are mainly interested in estimating
irs for regular genes. For i = 1, · · · , I and r = 1, · · · , R, let (t)ir be the posterior draw of
ir in the tth iteration of MCMC after the burn-in period, where t = 1, · · · , T , and T is the
total number of iterations. Then we can estimate ir by ˜ir =
PT
t=1 
(t)
ir /T . Similarly, we
can obtain a Bayesian estimate of ⇤ih for each housekeeping gene.
2.4. Simulation
2.4.1. Settings
We conducted three simulation studies to examine the performance of RCRnorm, and to
compare it with the three existing methods that have been proposed to normalize NanoS-
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tring nCounter data: NAPPA, NanoStringDiﬀ, and NanoStringNorm, as mentioned in the
introduction.
In the first study, five settings, labeled I-1 to I-5, were simulated based on the data model
proposed in Section 2.2.3. In our basic setting I-1, data were generated using parameter
values estimated from the FFPE samples in Section 2.5.1 for the lung cancer application.
Settings I-2 – I-5 were modified from I-1 to mimic diﬀerent real world scenarios.
1. The probed genes have larger variability in their expression levels. To simulate this
situation,   and  ⇤ were increased to 3 times that of the basic setting in I-2. These
two parameters control the signal strength, where a larger value indicates more genes
with strong signals and so it is easier to recover underlying expression levels.
2. The samples have larger lane-by-lane variation. This scenario mimics a poor control of
experimental conditions across diﬀerent samples or lanes, simulated in I-3 by increasing
 a and  b to 3 times that of the basic setting.
3. The probe library is poorly designed so that probes have larger variability in their
aﬃnity to diﬀerent gene targets. This scenario was simulated in I-4 by increasing  d
and  d  to 3 times that of the basic setting.
4. Eﬀects of random errors (unexplained variability) were examined in I-5 by increasing
 e and  e  to 3 times that of the basic setting.
In practice, the linear trend assumption in (2.2)-(2.5) is often robust, but the normality
assumption for probe-specific eﬀects and random errors may not always hold. In our second
study, we examined the robustness of RCRnorm when the normality assumption is violated.
We simulated another five settings by modifying the basic setting, labeled II-1 to II-5, using
a standard Student’s t distribution with three degrees of freedom (t3), which represents a
thick-tailed distribution, and a Gamma distribution with shape 2 and rate 1 (G2,1), which
represents a right-skewed distribution. In setting II-1, t3 was used to generate the probe
eﬀects {d+p }Pp=1, {d n }Nn=1, {d⇤h}Hh=1, {dr}Rr=1; and in II-2, t3 was used to generate the random
errors {e+ip}Pp=1, {e in}Nn=1, {e⇤ih}Hh=1, {eir}Rr=1. In II-3 and II-4, G2,1 was used to generate the
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probe eﬀects and random errors, respectively. In II-5, t3 was used to generate the probe
eﬀects and G2,1 to generate the random errors. Data generated from t3 were then rescaled to
have the same variance as in the basic setting I-1; and data generated from G2,1 were shifted
and rescaled to have mean 0 and the same variance as in I-1. Except for the changes above,
everything remains the same as in I-1.
Like the existing three methods, RCRnorm assumes a common sample eﬀect  i for all
genes in a given sample i to account for between-sample variations resulted from loading or
RNA degradation of diﬀerent samples. However, RNA degradation rates are diﬀerent among
genes as they are determined by a myriad of factors. The gene-wise RNA degradation from
either internal pathways or environmental conditions is technically diﬃcult to measure and
cannot be separated from true gene expression levels with current data using any of the four
methods. To understand how this uncertainty influences their performance, we designed
Study III, where  ir and  ⇤ih were generated from N(0,  2  ) and added to  i, and everything
else is again the same as in I-1. In settings III-1 to III-2, we set    to 0.1 and 0.4, respectively,
to study its potential eﬀect.
Under each setting, 50 datasets were independently simulated, each with 28 patient
samples, 6 positive controls, 8 negative controls, 7 housekeeping and 83 regular genes, which
are exactly the same as in the real lung cancer data. Since all the read counts were generated
in the log10 scale, they were exponentiated and rounded to the nearest integers so that the
simulated data can be analyzed by all the four algorithms. For RCRnorm, 8000 iterations
were simulated in each MCMC run and the first 5000 were used for burn-in. The existing
algorithms were applied using their default settings.
2.4.2. Results
To evaluate the performance on normalization under known truth, we computed gene-
wise Spearman correlations for 83 regular genes between normalized data and true expression
levels within each simulated dataset, and reported their mean, standard deviation (SD),
25th, 50th and 75th percentiles as the summary statistics for every method. Then under
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each setting, boxplots of these summary statistics based on 50 replicates were generated and
used to compare the four methods. Note that Spearman correlation was used instead of
Pearson correlation for a fair comparison. This is because RCRnorm works on the log10
scale, NAPPA on the log2 scale, and the other algorithms on the original scale; and so
Spearman correlation that ignores data values and relies on ranks only should be used.
Figure 2.2 shows boxplots of mean and SD, and Figure B.2 in appendix shows boxplots of
the 25th, 50th, and 75th percentiles, of gene-wise correlations for each of the five settings in
Simulation I. In the basic setting I-1, RCRnorm is a clear winner; and the existing algorithms
have somewhat similar performance, among which NanoStringDiﬀ seems to be a bit worse
than the other two because of its generally smaller mean, percentiles and larger SD as
well as the existence of outliers. This seems to be true in all the other settings except
for I-2, where they follow the order RCRnorm>NAPPA>NanoStringNorm>NanoStringDiﬀ
instead. In Setting I-2, the increased signal strength improves the performance of the existing
algorithms significantly. But it does not aﬀect RCRnorm much as it already performs well in
I-1. From settings I-3 to I-5, the increased variability, regardless of the source, worsens the
performance of every algorithm: compared to I-1, the mean and percentiles decrease but the
SD increases in general. The increase in probe-level variation (i.e.,  d and  d ) in Setting I-4
has the largest negative impact on the performance, followed by the increase in variability
of random noise (i.e.  e and  e ) in Setting I-5, and last by the increase in lane-by-lane
variation (i.e.,  a and  b) in Setting I-3. Among all, NanoStringDiﬀ is the most sensitive to
such changes and has extremely bad outliers, meaning that it fails to work sometimes. A
further investigation reveals that when running NanoStringDiﬀ, the generalized linear model
did not converge for some datasets. By contrast, RCRnorm is the least aﬀected by such
changes, and it maintains strong performance in all settings. Besides being well apart from
the other boxplots in all settings except for I-2, its boxplots show the smallest inter quartile
ranges, meaning that RCRnorm gives very consistent results over diﬀerent replicate datasets.
Figure 2.3, along with Figure B.3 in appendix, shows results for the five settings in Simu-
lation II. With these distributional disturbances added to the model system, the performance
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Figure 2.2. Simulation study I for mimicking various real-world scenarios: boxplots for mean and
SD of gene-wise Spearman correlations between normalized data and true expression levels based
on 50 replicates for each of the five settings I1-I5. Compared to the basic setting I-1 (parameter
values estimated from the FFPE samples in the lung cancer application), gene expression variability
is increased in I-2, lane-by-lane variation is increased in I-3, probe-level variation is increased in I-4,
and variability of random noise is increased in I-5. Note that NSnorm stands for NanoStringNorm
and NSdiﬀ for NanoStringDiﬀ.
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of every algorithm becomes worse, compared with I-1, as indicated by the generally wider
boxes and more occurrence of outliers for all the summary statistics. Typically, the changes
are not large except for NanoStringDiﬀ in Setting II-2 (i.e., heavy-tailed random errors),
where extremely bad outliers occur again. RCRnorm seems to be quite robust to these
moderate violations of the normality assumption and still outperforms the other methods.
Figure 2.4, along with Figure B.4 in appendix, shows results for the three settings in
Simulation III. With these experimentally unmeasurable gene-specific sample eﬀects added,
the performance of all the algorithms becomes worse as expected, when compared with I-1.
Although the performance deteriorates with increasing   , RCRnorm maintains the best
performance among the four.
2.5. Real data applications
2.5.1. Lung cancer data
We use the NanoString nCounter data from FFPE samples described in Section 2.2 to
illustrate the proposed RCRnorm first. We ran our MCMC algorithm for 15,000 iterations
in total. The convergence for all the model parameters was detected after 7,000 iterations,
and we discarded the first 10,000 for burn-in. We then thinned the chain to reduce the
autocorrelation among posterior draws by saving every tenth draw only, and so 500 posterior
samples were kept. Figure 2.5 shows the posterior densities of global parameters including µa,
µb, c,  ⇤,  ,  d,  d ,  e, and  e ; and Table 2.1 presents a summary for Bayesian estimates
of these parameters including the posterior mean, median, standard error (SE), and a 95%
credible interval (CI) using the 2.5th and 97.5th percentiles of (thinned) posterior samples.
Here, the posterior mean is used to estimate each location parameter; but the posterior
median is used to estimate each variance parameter since the corresponding posterior density
is skewed to the right.
Several intriguing observations can be made from the above figure and table. As we
know, housekeeping genes are involved in the maintenance of basic cellular function, and
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Figure 2.3. Simulation study II for robustness checking: boxplots for mean and SD of gene-wise
Spearman correlations between normalized data and true expression levels based on 50 replicates
for each of the five settings II1-II5. In II1, a thick-tail distribution t3 was used to simulate probe
eﬀects; in II-2, t3 was used to simulate random errors; in II-3, a right-skewed distribution G2,1was
used to simulate probe eﬀects; in II-4, G2,1 was used to simulate random errors; and in II-5, t3 was
used to generate probe eﬀects and G2,1 to generate random errors. Except for the changes above,
everything remains the same as in the basic setting I-1 including all parameter values (so t3 and
G2,1 need to be rescaled or shifted). Note that NSnorm stands for NanoStringNorm and NSdiﬀ for
NanoStringDiﬀ.
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Figure 2.4. Simulation study III for mimicking diﬀerent RNA degradation levels between genes:
boxplots for mean and SD of gene-wise Spearman correlations between normalized data and true
expression levels based on 50 replicates for each of the two settings III1-III2, where  ir and  ⇤ih were
generated from a normal distribution with mean 0 and SD 0.1 and 0.4, respectively. Note that
NSnorm stands for NanoStringNorm and NSdiﬀ for NanoStringDiﬀ.
mean median SD 95% CI
µa 2.462 2.462 0.014 (2.436, 2.490)
µb 0.927 0.927 0.003 (0.922, 0.932)
c -1.877 -1.872 0.125 (-2.126, -1.635)
 ⇤ 0.138 0.136 0.011 (0.121, 0.163)
  0.361 0.361 0.007 (0.349, 0.375)
 d  0.333 0.308 0.104 (0.198, 0.595)
 d 0.129 0.120 0.045 (0.074, 0.242)
 e  0.211 0.211 0.011 (0.189, 0.233)
 e 0.035 0.035 0.003 (0.031, 0.041)
Table 2.1. Lung cancer data: posterior summary statistics of global parameters from applying
RCRnorm to FFPE samples
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Figure 2.5. Lung cancer data: posterior densities of global parameters from applying RCRnorm
to FFPE samples
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so are expected to be uniformly expressed with low variability in all cells and experimental
conditions. Our analysis using RCRnorm confirms that, compared to other genes, expression
levels of housekeeping genes indeed vary much less. Clearly, the Bayesian estimate of  ⇤
(0.136, the SD of expression levels for housekeeping genes) is much smaller than that of  
(0.361, the SD of expression levels for regular genes); and Figure 2.5(b) shows their posterior
density curves are well separated with the correct order. Further, our exploratory analysis in
Section 2.2.2 strongly indicates  d <  d  and  e <  e . That is, the SD of the probe-specific
deviation (from the linear trend) for negative controls is larger than that for the other types
of probes; so does the SD of the random errors. The Bayesian estimates in Table 2.1 confirm
the underlying features again (0.120<0.308 and 0.035<0.211) and the posterior densities in
Figure 2.5(e) and (f) support them as well. Note that the data model of RCRnorm does
not impose such order constraints at all, but the end results from RCRnorm capture these
characteristics accurately.
Next, we compare the performance of RCRnorm in normalizing FFPE data with the
existing algorithms. As FF samples generally have much better quality than FFPE samples,
we used normalized FF data as a gold standard, where each method was applied to normalize
both FFPE and FF data, and Pearson correlations between normalized FFPE and FF data
were computed to quantify its performance. The summary statistics (mean, SD, 25%, 50%
and 75% quantile) of 83 gene-wise correlations are presented in the left panel of Table 2.2,
with the best value bolded in each column. Compared to the original data, all algorithms
significantly improve the gene-wise correlations; and RCRnorm has the best performance in
terms of higher mean and percentiles as well as smaller variability. Note that the existing
algorithms have somewhat similar performance, though NAPPA seems to be slightly better
than the other two. However, RCRnorm can further oﬀer a sizable gain over their already
improved performance.
Although gene-wise correlations are the focus of the original study (Xie et al., 2017) for
validating the gene signature, we also report 28 patient-wise correlations in the right panel
of Table 2.2. Here, only RCRnorm and NAPPA are able to adjust patient-wise correlations.
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Gene-wise Pearson correlation Patient-wise Pearson correlation
mean SD 25% 50% 75% mean SD 25% 50% 75%
Original data 0.291 0.278 0.114 0.303 0.444 0.806 0.129 0.720 0.835 0.897
RCRnorm 0.550 0.197 0.427 0.590 0.694 0.851 0.102 0.792 0.876 0.926
NAPPA 0.488 0.194 0.370 0.522 0.646 0.844 0.102 0.793 0.863 0.919
NanoStringDiﬀ 0.487 0.207 0.352 0.496 0.635 0.806 0.129 0.720 0.835 0.897
NanoStringNorm 0.489 0.199 0.341 0.474 0.630 0.806 0.129 0.720 0.835 0.897
Table 2.2. Lung cancer data: summary statistics of Pearson correlation coeﬃcients between nor-
malized FFPE and FF samples using diﬀerent algorithms
This is because NanoStringDiﬀ and NanoStringNorm linearly transform a patient’s data
with scale factors calculated from internal controls and thus do not change the patient-wise
correlations. By contrast, both RCRnorm and NAPPA achieve some improvement from
normalization, though it is not as big as seen in the gene-wise case. This is perhaps because
the patient-wise correlations of the original data are already high and so there is not much
room left for improvement. Again, RCRnorm seems to be better than NAPPA with higher
mean, percentiles and about the same variability.
It is interesting to observe that for the unnormalized data, the patient-wise correlations
(mean: 0.806, SD: 0.129) are much higher than the gene-wise correlations (mean: 0.291, SD:
0.278). The high patient-wise correlations indicate the superb performance of NanoString
nCounter on expression profiling with FFPE samples. On the other hand, the much lower
patient-wise correlations highlight the importance of removing sample-specific eﬀects for
downstream statistical analysis.
In this application, the gene-wise correlations achieved by all the four algorithms are
generally lower than what we have seen in our simulation. This can be explained by the
following reasons. Firstly, due to experimental and technical limitations, gene-wise RNA
degradation levels cannot be measured and removed by any of the four algorithms. As
shown in Figure 2.4, such variation could cause a large drop in performance. Secondly,
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normalized FF expression levels were used to calculate the correlations in the application
while true expression levels were used in the simulation.
2.5.2. Colorectal cancer data
Our second application involves a colorectal cancer study (Omolo et al., 2016) that com-
pared five diﬀerent platforms to identify which platform could faithfully translate the RAS
pathway gene signature identified from FF samples into FFPE samples. RAS pathway ac-
tivation is a risk factor for the failure of EGFR combination therapy in colorectal cancer
patients. Thus, it is clinically important to identify a platform that could obtain reliable in-
formation from FFPE samples. Among the 5 platforms compared, NanoString nCounter was
found to be the best platform to recover gene expression information from FFPE samples.
We applied RCRnorm to the NanoString nCounter data from FFPE samples in this study,
where, again, 15,000 iterations were used with the first 10,000 being burn in. The dataset
contains 54 samples, with 6 positive controls (with the same input amounts as before), 6
negative controls, 11 housekeeping and 18 regular genes. Thus, unlike the lung cancer data,
it has more samples than probes.
Figure B.5 plots posterior densities and Table B.2 reports posterior summary statistics
of global parameters in appendix. Compared with Table 2.1 in the lung cancer study, the
estimates of µa, µb and c are all close, although they are completely from two independent
and distinct studies. Again, the Bayesian estimates of  ⇤ and   (0.190 vs. 0.278) confirm
that expression levels of the housekeeping genes vary less than those of the regular genes.
Interestingly,  ⇤ in this study is larger than that in the lung cancer study (estimate: 0.190 >
0.136; 95% CI: (0.176, 0.215) completely above (0.121, 0.163)), although more housekeeping
genes were used here (11 vs. 7). This seems to suggest that increasing the number of
housekeeping genes used does not necessarily reduce their variability to the minimal level.
Our results further confirm that  d ⌧  d  (0.069 vs. 0.257) and  e ⌧  e  (0.042 vs.
0.273). Recall that these characteristics were revealed by exploring the lung cancer data.
Nevertheless, they may generally hold for NanoString nCounter data of any kind.
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In this study, paired FF NanoString data are not available, and so performance com-
parison among the four methods cannot be done using correlations between normalized
FFPE and FF data. According to the manual of NanoStringNorm (Waggott et al., 2012),
housekeeping genes are typically selected to be genes with high means and low standard de-
viations . Thus, the two-sample t test was used to compare the coeﬃcients of variation (CV
= SD/mean) between the housekeeping and regular genes. A good normalization algorithm
should have a clear separation of CVs between these two types of genes. To make the CVs
from the four algorithms comparable, we transformed the normalized data from the four
algorithms into the same scale. In Table 2.3, RCRnorm not only has the smallest two-sided
p value, but also confirms the existence of a significant diﬀerence between the two gene types
at a significance level 0.05. None of the existing methods was able to do so. This suggests
the superior performance of RCRnorm in normalizing NanoString data.
RCRnorm NAPPA NanoStringDiﬀ NanoStringNorm
p value 0.036 0.146 0.170 0.096
Table 2.3. Colorectal cancer data: two-sided p values from the t test that compares the CVs
between housekeeping and regular genes
2.6. Discussion
Motivated by a lung cancer study in predicting adjuvant chemotherapy (ACT) response,
we have developed a novel (Bayesian) method, RCRnorm, to normalize NanoString nCounter
data. Through simulation studies, we have shown that RCRnorm compares very favorably
with the existing methods, especially for situations with an elevated level of heterogeneity
from various sources. In the lung cancer application, RCRnorm performs the best, and
greatly improves gene-wise correlations between paired FF and FFPE samples. Thus, it oﬀers
an important move toward applying gene signatures identified from genome-wide expression
profiling of FF samples into wide clinical use with FFPE samples. Meanwhile, it provides
improved patient-wise correlations while NanoStringDiﬀ and NanoStringNorm cannot.
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The competitive performance of RCRnorm can be largely explained by two unique fea-
tures it owns. First of all, RCRnorm relies on an integrated system of hierarchical linear
regression models with random coeﬃcients, which eﬀectively captures mean structures un-
derlying the data shared among diﬀerent types of probes, to maximally remove systematic
sample-specific biases in gene expression profiling. Unlike RCRnorm, the previous methods
use the diﬀerent types of internal controls in an isolated and somewhat heuristic manner.
Thus, they do not take full advantage of the rich information provided by the nCounter
system. Secondly, the existing methods adjust sample loading eﬀects with information ex-
tracted from housekeeping genes. This is based on the assumption that expression levels of
housekeeping genes are stable across samples, implying that their biological variability in
gene expression is zero. In practice, their biological variability, although smaller than other
genes in general, is not zero. Some housekeeping genes have been reported to have significant
fluctuations (Gubern et al., 2009). Thus, this simplifying assumption may lead to compro-
mised performance of the existing methods on normalization. By contrast, RCRnorm does
not need the assumption as two separate variance terms,  2⇤ and  2, are used to model the
biological variability of housekeeping and regular genes, respectively. Further, by estimating
and comparing  2⇤ and  2, RCRnorm can provide an alternative way to examine the validity
of housekeeping genes used in an nCounter system from an analytical perspective.
In addition, RCRnorm oﬀers much better interpretability than the other methods. It is
based on a rigorous model system, whose parameters can be intuitively interpreted. With
estimates obtained from the Bayesian approach, researchers can gain a deep understanding
about the dataset under study. Moreover, in the integrated system, X represents the log
RNA content, whose value is attached with a unit log fM. So for housekeeping and regular
genes, the quantity of interest , which is an additive term that makes up X, should have
the same unit. Thus, the normalized expression produced by RCRnorm also has the unit
log fM so that their values are directly comparable to the input amounts of positive controls
in the system. This may help us concretely understand how high a gene is expressed.
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RCRnorm employs a Bayesian framework to handle its computational needs, and so
a non-informative prior setup, as detailed in Section 2.3.2, is adopted. In situations when
meaningful prior knowledge is available, prior distributions can be chosen to incorporate such
knowledge for improved results. We have developed an eﬃcient Gibbs sampler for posterior
computation and inference, where all the steps can be done by direct sampling from known
distributions. Based on our numerical experience, the algorithm is computationally stable
and converges without manual tuning in all our settings. In the lung cancer application, it
took ⇠ 1000 seconds to run 15,000 iterations using R on a 2.8 GHz Intel Core i7 processor.
Note that based on the proposed model system, frequentist approaches to estimation such
as maximum likelihood and nonparametric methods may be used to facilitate computation.
Nevertheless, RCRnorm oﬀers the advantage of quantifying the estimation uncertainty easily
as it is Bayesian in nature. The existing algorithms, which are all frequentist, cannot even
provide confidence intervals for key parameters or normalized expression.
RCRnorm is a method designed based on characteristics of nCounter data observed from
FFPE samples. However, the proposed model system does not impose restrictive assump-
tions that can limit its application to other nCounter data such as those from FF samples.
It can also be used with other platforms that use internal controls (with minor adaptions).
Further, replicates from the same patient, when available, can be naturally incorporated into
the system to enable better estimation of model parameters and normalized expression. This
is because RCRnorm, again as a Bayesian method, has the capability to pool information
from various sources such as probes, patients, replicates. The other methods can only treat
the replicates as independent samples and then calculate the mean or median of normalized
expression levels to combine replicates.
Although current technologies cannot reliably quantify RNA degradation levels in FFPE
samples, clinical information for these samples such as age of FFPE samples (not the patient
age) and RIN (RNA integrity number; a measure used to evaluate RNA quality) (Von Ahlfen
et al., 2007), if available, can be integrated to model the degradation levels, to potentially
improve the performance on normalization.
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Finally, we mention that applying diﬀerent normalization methods can alter results of
downstream analysis. Thus, integrated strategies that add additional structures into the
constructed model system can be developed for a routine analysis task, which automatically
removes the uncertainty related to normalized expression.
2.7. R package
The proposed method RCRnorm has been implemented by an open source R package
that is downloadable from CRAN: https://cran.r-project.org/web/packages/RCRnorm/ .
The main function in the package is named ’RCRnorm’. This function uses the raw read
count data from NanoString platform with data for each probe type stored as an element in
a list. Users can choose the number of burn in cycles and total number of iterations for the
Gibbs sampler. Starting point for the Gibbs sampler can be set to be random or roughly
estimated from the data. For fast convergence, starting point is set to be roughly estimated
from the data by default. The Gibbs sampler is implemented with the full conditional
densities specified as in appendix B.2.
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Appendix A
PBNPA: A PERMUTATION-BASED NON-PARAMETRIC ANALYSIS OF CRISPR
SCREEN DATA
A.1. Figures
Figure A.1 shows the result of simulation evaluation of positive selection performance
using datasets with an increased over-dispersion level while fixing the number of sgRNAs
per gene. Figure A.2 shows the result of simulation evaluation of positive selection perfor-
mance using datasets with an increased over-dispersion level while fixing the proportion of
oﬀ target sgRNAs. Figure A.3 shows the result of simulation evaluation of negative selection
performance using datasets with an increased over-dispersion level while fixing the number
of sgRNAs per gene. Figure A.4 shows the result of simulation evaluation of negative se-
lection performance using datasets with an increased over-dispersion level while fixing the
proportion of oﬀ target sgRNAs.
A.2. R package code for PBNPA
#Used to analyze single dataset (real data used by mageck paper).
get.median = function(x, y, func)
{
return(tapply(y, x, func)) ##### mean vs median
}
#get permutated p.values. x is an element, y is a vector contains all permutated values.
get.pos.permu.p = function(x, y)
{
pos.p = sum(y > x, na.rm = T)/length(y)
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Figure A.1. Simulation evaluation of positive selection performance using datasets with an
increased over-dispersion level. ROC curves and AUCs are shown for diﬀerent algorithms
with an increasing oﬀ target proportion while fixing the number of sgRNAs per gene at 3.
Each curve represents the average of ROC curves for 50 simulated datasets and hereafter.
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Figure A.2. Simulation evaluation of positive selection performance using datasets with an
increased over-dispersion level. ROC curves and AUCs are shown for diﬀerent algorithms
with an increasing number of sgRNAs per gene while fixing the oﬀ target proportion at 10%.
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Figure A.3. Simulation evaluation of negative selection performance using datasets with an
increased over-dispersion level. ROC curves and AUCs are shown for diﬀerent algorithms
with an increasing oﬀ target proportion while fixing the number of sgRNAs per gene at 3.
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Figure A.4. Simulation evaluation of negative selection performance using datasets with an
increased over-dispersion level. ROC curves and AUCs are shown for diﬀerent algorithms
with an increasing number of sgRNAs per gene while fixing the oﬀ target proportion at 10%.
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Figure A.5. Simulation evaluation of negative selection performance based on recall, precision
and F_1 for diﬀerent combinations of sgRNA number per gene (2~6) and oﬀ target ratio.
Each bar represents the average of 50 simulated datasets and standard error is indicated on
the bar.
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return(pos.p)
}
get.neg.permu.p = function(x, y)
{
neg.p = sum(y < x, na.rm = T)/length(y)
return(neg.p)
}
#zs.gene: calculated stat for each gene according to the function
permu.pvalue = function(dat, sim.no = sim.no, zs.gene, func, seed = 7292016)
{
zs = log(dat[,4]/dat[,3])
set.seed(seed)
index.mat = matrix(rep(dat$Gene, sim.no), ncol = sim.no)
permu.index.mat = apply(index.mat, 2, sample) #each column is a permutation of the
original gene index.
result.mat = apply(permu.index.mat, 2, get.median, y = zs, func)
pos.p = sapply(zs.gene, get.pos.permu.p, as.vector(result.mat))
neg.p = sapply(zs.gene, get.neg.permu.p, as.vector(result.mat))
return(data.frame(pos.p, neg.p))
}
#dataset.id is the id number for simulated dataset name; oﬀ.ratio is the oﬀ target pro-
portion in the simulated dataset
fold.crispr = function(dat,sim.no = 10, func = "median", alpha.threshold = .2)
{
dat = dat[order(dat$Gene), ] # so that data set is in increasing order of gene
dat[is.na(dat)] = 0
dat[, 3:4] = dat[, 3:4] + .25
datt = dat
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dat[, 3] = datt[, 3] * mean(c(sum(datt[, 3]), sum(datt[, 4])))/sum(datt[, 3])
dat[, 4] = datt[, 4] * mean(c(sum(datt[, 3]), sum(datt[, 4])))/sum(datt[, 4])
zs.gene = tapply(log(dat[,4]/dat[,3]), dat$Gene, func) #### mean vs median
initial.p.value = permu.pvalue(dat, sim.no = sim.no, zs.gene = zs.gene, func = func)
initial.adj.pos.pvalue = initial.p.value$pos.p
initial.adj.neg.pvalue = initial.p.value$neg.p
initial.result = data.frame(Gene = sort(unique(dat$Gene)), initial.adj.pos.pvalue, ini-
tial.adj.neg.pvalue)
#summarize genes selected by the program
initial.pos.gene = initial.result$Gene[initial.adj.pos.pvalue < alpha.threshold]
initial.neg.gene = initial.result$Gene[initial.adj.neg.pvalue < alpha.threshold]
update.dat = dat[!is.element(dat$Gene, c(initial.pos.gene, initial.neg.gene)),]
p.value = permu.pvalue(update.dat, sim.no = sim.no, zs.gene = zs.gene, func = func)
final.result = data.frame(Gene = sort(unique(dat$Gene)), pos.pvalue = p.value$pos.p,
neg.pvalue = p.value$neg.p)
return(final.result)
}
PBNPA = function(dat, sim.no = 10, alpha.threshold = .2, fdr = .05)
{
nrep = length(dat)
combine.pos = list()
combine.neg = list()
for (i in 1:nrep)
{
result = fold.crispr(dat[[i]], sim.no = sim.no, alpha.threshold = alpha.threshold)
combine.pos[[i]] = result$pos.pvalue
combine.neg[[i]] = result$neg.pvalue
}
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combined.pos = metaRNASeq::fishercomb(combine.pos, BHth = fdr)
combined.neg = metaRNASeq::fishercomb(combine.neg, BHth = fdr)
final.result = data.frame(Gene = sort(unique(dat[[1]]$Gene)),
pos.pvalue = combined.pos$rawpval, pos.fdr = combined.pos$adjpval,
neg.pvalue = combined.neg$rawpval, neg.fdr = combined.neg$adjpval)
pos.gene = final.result$Gene[combined.pos$DEindices] #genes that are selected as posi-
tive genes.
neg.gene = final.result$Gene[combined.neg$DEindices] #genes that are selected as neg-
ative genes.
pos.no = length(pos.gene)
neg.no = length(neg.gene)
return.value = list(pos.gene = pos.gene, pos.no = pos.no, neg.gene = neg.gene, neg.no
= neg.no, final.result = final.result)
return(return.value)
}
62
Appendix B
RCRNORM: AN INTEGRATED SYSTEM OF RANDOM-COEFFICIENT
HIERARCHICAL REGRESSION MODELS FOR NORMALIZING NANOSTRING
NCOUNTER DATA FROM FFPE SAMPLES
B.1. Tables and figures
B.1.1. Additional information about lung cancer data
CodeClass Name Patient_1 ... Patient_i ... Patient _I
Negative Control Neg_A(0) Y  11 ... Y
 
i1 ... Y
 
I1
... ... ... ... ... ... ...
Negative Control Neg_H(0) Y  18 ... Y
 
i8 ... Y
 
I8
Positive Control Pos_A(128) Y +11 ... Y
+
i1 ... Y
+
I1
... ... ... ... ... ... ...
Positive Control Pos_F(0.125) Y +16 ... Y
+
i6 ... Y
+
I6
Housekeeping Gene Gene*_1 Y ⇤11 ... Y ⇤i1 ... Y ⇤I1
... ... ... ... ... ... ...
Housekeeping Gene Gene*_7 Y ⇤17 ... Y ⇤i7 ... Y ⇤I7
Regular Gene Gene_1 Y11 ... Yi1 ... YI1
... ... ... ... ... ... ...
Regular Gene Gene_87 Y1,87 ... Yi,87 ... YI,87
Table B.1. Lung cancer data: data structure from the NanoString nCounter platform
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Figure B.1. Lung caner data: read counts of 6 positive controls from FFPE samples of the 28
patients. The legend shows that the amount of RNA targeted by each of the six probes.
B.1.2. Additional simulation results
Figure B.2, B.3 and B.4 showed the above mentioned simulation results of diﬀerent
percentiles.
B.1.3. Results for colorectal cancer data
Table B.2 and figure B.5 showed the additional results for colorectal cancer data.
B.2. Full conditionals
Let ✓|... denote ✓ given the observed data and all the other parameters and latent variables
(i.e., ✓|Y ,⇥ ✓). The full conditional posterior distributions based on the priors specified in
Section 2.3 are given below.
1. For i = 1, · · · , I,
ai|... ⇠ N
 A1
 2e 
+ A2+A3+A4 2e +
µa
 2a
N
 2e 
+ P+H+R 2e +
1
 2a
,
1
N
 2e 
+ P+H+R 2e +
1
 2a
!
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Figure B.2. Simulation study I for mimicking various real-world scenarios: boxplots for 25th,
50th and 75th percentiles of gene-wise Spearman correlations between normalized data and true
expression levels based on 50 replicates for each of the five settings I1-I5. Compare to the basic
setting I-1 (parameter values estimated from the FFPE samples in the lung cancer application),
gene expression variability is increased in I-2, lane-by-lane variation is increased in I-3, probe-level
variation is increased in I-4, and variability of random noise is increased in I-5. Note that NSnorm
stands for NanoStringNorm and NSdiﬀ for NanoStringDiﬀ.
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Figure B.3. Simulation study II for robustness checking: boxplots for 25th, 50th and 75th per-
centiles of gene-wise Spearman correlations between normalized data and true expression levels
based on 50 replicates for each of the five settings II1-II5. In II1, a thick-tail distribution t3 was
used to simulate probe eﬀects; in II-2, t3 was used to simulate random errors; in II-3, a right-skewed
distribution G2,1was used to simulate probe eﬀects; in II-4, G2,1 was used to simulate random errors;
and in II-5, t3 was used to generate probe eﬀects and G2,1 to generate random errors. Except for the
changes above, everything remains the same as in the basic setting I-1 including all parameter values
(so t3 and G2,1 need to be rescaled or shifted). Note that NSnorm stands for NanoStringNorm and
NSdiﬀ for NanoStringDiﬀ.
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Figure B.4. Simulation study III for mimicking diﬀerent RNA degradation levels between genes:
boxplots for 25th, 50th and 75th percentiles of gene-wise Spearman correlations between normalized
data and true expression levels based on 50 replicates for each of the two settings III1-III2, where
 ir and  ⇤ih were generated from a normal distribution with mean 0 and SD 0.1 and 0.4, respectively.
Note that NSnorm stands for NanoStringNorm and NSdiﬀ for NanoStringDiﬀ.
mean median SD 95% CI
µa 2.281 2.281 0.004 (2.274, 2.290)
µb 0.946 0.946 0.002 (0.942, 0.949)
c -1.750 -1.720 0.177 (-2.238, -1.499)
 ⇤ 0.191 0.190 0.010 (0.176, 0.215)
  0.279 0.278 0.010 (0.264, 0.303)
 d  0.289 0.257 0.139 (0.127, 0.708)
 d 0.075 0.069 0.026 (0.041, 0.144)
 e  0.273 0.273 0.011 (0.250, 0.295)
 e 0.042 0.042 0.002 (0.039, 0.047)
Table B.2. Colorectal cancer data: posterior summary statistics of global parameters from applying
RCRnorm to FFPE samples
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Figure B.5. Colorectal cancer data: posterior densities of global parameters from applying
RCRnorm to FFPE samples
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12. For global parameters c, µa, µb,
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In our preliminary experiments, we find that updating  2d only using data from positive
controls would greatly facilitate the convergence of the algorithm while achieving almost the
same results. Thus, in our R package named RCRnorm,  2d is updated using
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B.3. R package code for RCRnorm
#get coeﬃcient of linear regression from positive ctrl
fitWithPosCtrl = function(y, x)
{
mod1 = stats::lm(y ~ x)
coefs = stats::coef(mod1)
unname(coefs)
}
#get prior range of uniform distribution
get_range = function(x, mm = 5)
{
c(mean(x)-mm*stats::sd(x), mean(x)+mm*stats::sd(x))
}
#get residual from positive ctrl fitted with simple linear regression
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get_residual = function(log_dat, RNA_conc, coefs)
#in matrix format
{
log_dat - sweep(sweep(RNA_conc, 2, coefs[2, ], ’*’), 2, coefs[1, ], ’+’)
}
#main function to implement RCRnorm
RCRnorm = function(dat, pos_conc = log10(c(128, 32, 8, 2, 0.5, 0.125)), iter = 8000,
warmup = 5000, random_init = F, all_dat = T, seed = 1, mm = 3, m_ab = 9)
{
ptm <- proc.time()
set.seed(seed*3723)
#log10 transform the original count data
pos_dat = log10(dat$pos_dat + 1)
neg_dat = log10(dat$neg_dat + 1)
hk_dat = log10(dat$hk_dat + 1)
reg_dat = log10(dat$reg_dat + 1)
#inverse gamma parameter
u = v = .01
#number of each class of genes.
n_hk = dim(hk_dat)[1]
n_reg = dim(reg_dat)[1]
n_neg = dim(neg_dat)[1]
n_pos = dim(pos_dat)[1]
#number of patients or samples
n_patient = dim(pos_dat)[2]
#number of MCMC iteration used to calculate posterior after convergence
iter_keep = iter - warmup
#calculate the coeﬃcient for each patient; note: with positive controls.
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# all_coef: First row: a+5se; second row: b+5se; third row: a-5se; fourth row: b-5se.
all_coef = apply(pos_dat, 2, fitWithPosCtrl, pos_conc)
mu_a_itm = mean(all_coef[1,])
mu_b_itm = mean(all_coef[2,])
#Jacknife to estimate mean and variance of mu_a and mu_b
mu_a = numeric()
mu_b = numeric()
for (i in 1:500)
{
mu_a[i] = mean(sample(all_coef[1, ], n_patient - 2))
mu_b[i] = mean(sample(all_coef[2, ], n_patient - 2))
}
mu_a_mu = mean(mu_a)
cat(mu_a_mu, ’\n’)
mu_b_mu = mean(mu_b)
cat(mu_b_mu, ’\n’)
sigma2_mu_a = m_ab * stats::var(mu_a)
cat(sigma2_mu_a, ’\n’)
sigma2_mu_b = m_ab * stats::var(mu_b)
cat(sigma2_mu_b, ’\n’)
hk_RNA = sweep(sweep(hk_dat, 2, all_coef[1,], ’-’), 2, all_coef[2,], ’/’)
reg_RNA = sweep(sweep(reg_dat, 2, all_coef[1,], ’-’), 2, all_coef[2,], ’/’)
##estimate genes’ mean expression level range
lambda_hk_range = apply(hk_RNA, 1, get_range, mm = mm)
lambda_reg_range = apply(reg_RNA, 1, get_range, mm = mm)
#estimate patient eﬀect range by two way ANOVA with patient’s regular gene expression
level.
gene = factor(rep(1:n_reg, n_patient))
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patient = factor(rep(1:n_patient, each = n_reg))
mod = stats::lm(unlist(reg_RNA) ~ patient + gene, contrasts = list(patient = ’contr.sum’,
gene = ’contr.sum’))
phi = numeric(n_patient)
phi[1:(n_patient - 1)] = summary(mod)$coeﬃcients[2:n_patient, 1]
phi[n_patient] = -sum(phi)
phi_L = phi - mm * summary(mod)$coeﬃcients[2, 2]
phi_U = phi + mm * summary(mod)$coeﬃcients[2, 2]
#initialize all the parameters
aa = matrix(NA, ncol = n_patient, nrow = iter_keep)
bb = matrix(NA, ncol = n_patient, nrow = iter_keep)
cc = numeric(iter_keep)
phi_return = matrix(NA, ncol = n_patient, nrow = iter_keep) #patient eﬀect
kappa_hk = matrix(NA, ncol = n_patient * n_hk, nrow = iter_keep)
kappa_reg = matrix(NA, ncol = n_patient * n_reg, nrow = iter_keep)
lambda_hk = matrix(NA, ncol = n_hk, nrow = iter_keep)
lambda_reg = matrix(NA, ncol = n_reg, nrow = iter_keep)
d_neg = matrix(NA, ncol = n_neg, nrow = iter_keep)
d_pos = matrix(NA, ncol = n_pos, nrow = iter_keep)
d_hk = matrix(NA, ncol = n_hk, nrow = iter_keep)
d_reg = matrix(NA, ncol = n_reg, nrow = iter_keep)
mu_a = numeric(iter_keep)
mu_b = numeric(iter_keep)
sigma2e_neg = numeric(iter_keep)
sigma2e_phr = numeric(iter_keep)
sigma2a = numeric(iter_keep)
sigma2b = numeric(iter_keep)
sigma2kappa_hk = numeric(iter_keep)
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sigma2kappa_reg = numeric(iter_keep)
sigma2d_neg = numeric(iter_keep)
sigma2d_phr = numeric(iter_keep)
if (random_init == T)
{
sigma2a_itm = stats::runif(1, 0, .01)
sigma2b_itm = stats::runif(1, 0, .01)
a_itm = stats::rnorm(n_patient, 2.5, .1)
b_itm = stats::rnorm(n_patient, .9, .1)
cc_itm = stats::runif(1, -6, -1)
phi_itm = stats::rnorm(n_patient, 0, 2)
phi_itm[n_patient] = -sum(phi_itm[1:(n_patient - 1)])
kappa_hk_itm = stats::rnorm(n_hk * n_patient, 0, 1)
sigma2kappa_hk_itm = stats::runif(1, 0, 1)
kappa_reg_itm = stats::rnorm(n_reg * n_patient, 0, 1)
sigma2kappa_reg_itm = stats::runif(1, 0, 1)
lambda_hk_itm = stats::rnorm(n_hk, 0, 1)
lambda_reg_itm = stats::rnorm(n_reg, 0, 1)
d_neg_itm = stats::rnorm(n_neg, 0, .01)
sigma2d_neg_itm = stats::runif(1, 0, .1)
d_pos_itm = stats::rnorm(n_pos, 0, .01)
sigma2d_phr_itm = stats::runif(1, 0, .1)
d_hk_itm = stats::rnorm(n_hk, 0, .01)
d_reg_itm = stats::rnorm(n_reg, 0, .01)
sigma2e_neg_itm = stats::runif(1, 0, .1)
sigma2e_phr_itm = stats::runif(1, 0, .1)
}
#get initial values; itm: intermediate
76
if (random_init == F)
{
sigma2a_itm = stats::var(all_coef[1,])
sigma2b_itm = stats::var(all_coef[2,])
a_itm = all_coef[1,]
b_itm = all_coef[2,]
cc_itm = mean(unlist(sweep(sweep(neg_dat, 2, all_coef[1,], ’-’), 2, all_coef[2,], ’/’)))
phi_itm = phi lambda_hk_itm = apply(lambda_hk_range, 2, mean)
lambda_reg_itm = apply(lambda_reg_range, 2, mean)
estimate_kappa = sweep(rbind(hk_RNA, reg_RNA), 2, phi_itm, ’-’)
estimate_kappa_var = sweep(sweep(rbind(hk_RNA, reg_RNA), 2, phi_itm, ’-’), 1,
c(lambda_hk_itm, lambda_reg_itm), ’-’)
kappa_hk_itm = as.vector(unlist(estimate_kappa[1:n_hk,]))
sigma2kappa_hk_itm = stats::var(as.vector(unlist(estimate_kappa_var[1:n_hk,])))
kappa_reg_itm = as.vector(unlist(estimate_kappa[(1+n_hk):(n_hk+n_reg),]))
sigma2kappa_reg_itm = stats::var(as.vector(unlist(estimate_kappa_var[(1+n_hk):
(n_hk+n_reg),])) )
pos_RNA = matrix(rep(pos_conc, n_patient), ncol = n_patient)
neg_RNA = matrix(rep(cc_itm, n_neg * n_patient), ncol = n_patient)
d_neg_itm = apply(get_residual(neg_dat, neg_RNA, all_coef), 1, mean)
sigma2d_neg_itm = stats::var(d_neg_itm)
d_pos_itm = apply(get_residual(pos_dat, pos_RNA, all_coef), 1, mean)
sigma2d_phr_itm = stats::var(d_pos_itm)
d_hk_itm = rep(0, n_hk)
d_reg_itm = rep(0, n_reg)
sigma2e_neg_itm = stats::var(unlist(sweep(get_residual(neg_dat, neg_RNA, all_coef),
1, d_neg_itm, ’-’)))
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sigma2e_phr_itm = stats::var(unlist(sweep(get_residual(pos_dat, pos_RNA, all_coef),
1, d_pos_itm, ’-’)))
}
for (i in 1:iter)
{
A2 = colSums(sweep(pos_dat - pos_conc %o% b_itm, 1, d_pos_itm, ’-’))
B2 = colSums(sweep(sweep(sweep(pos_dat, 2, a_itm, ’-’), 1, d_pos_itm, ’-’), 1, pos_conc,
’*’))
if (all_dat == F)
{
a_itm = stats::rnorm(rep(1, n_patient), ((A2)/sigma2e_phr_itm
+ mu_a_itm/sigma2a_itm)/ ((n_pos)/sigma2e_phr_itm + 1/sigma2a_itm),
sqrt(1/((n_pos)/sigma2e_phr_itm + 1/sigma2a_itm)))
b_itm = stats::rnorm(rep(1, n_patient), ((B2)/sigma2e_phr_itm
+ mu_b_itm/sigma2b_itm)/ ((sum(pos_conc^2))/sigma2e_phr_itm
+ 1/sigma2b_itm), sqrt(1/((sum(pos_conc^2))/
sigma2e_phr_itm + 1/sigma2b_itm)))
} else
{
A1 = colSums(sweep(sweep(neg_dat, 2, b_itm*cc_itm, ’-’), 1, d_neg_itm, ’-’))
A3 = colSums(sweep(hk_dat - matrix(rep(b_itm, each = n_hk) * (rep(phi_itm, each
= n_hk) + kappa_hk_itm), nrow = n_hk), 1, d_hk_itm, ’-’))
A4 = colSums(sweep(reg_dat - matrix(rep(b_itm, each = n_reg) * (rep(phi_itm, each
= n_reg) + kappa_reg_itm), nrow = n_reg), 1, d_reg_itm, ’-’))
a_itm = stats::rnorm(rep(1, n_patient), ((A1/sigma2e_neg_itm) + (A2+A3+A4)/
sigma2e_phr_itm + mu_a_itm/sigma2a_itm)/ (n_neg/
sigma2e_neg_itm + (n_pos+n_hk+n_reg)/sigma2e_phr_itm
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+ 1/sigma2a_itm), sqrt(1/(n_neg/sigma2e_neg_itm + (n_pos+n_hk+n_reg)/
sigma2e_phr_itm + 1/sigma2a_itm)))
B1 = cc_itm * colSums(sweep(sweep(neg_dat, 2, a_itm, ’-’), 1, d_neg_itm, ’-’))
B3 = colSums(matrix(rep(phi_itm, each = n_hk) + kappa_hk_itm,
nrow = n_hk)*sweep(sweep(hk_dat, 2, a_itm, ’-’), 1, d_hk_itm, ’-’))
B4 = colSums(matrix(rep(phi_itm, each = n_reg) + kappa_reg_itm,
nrow = n_reg)*sweep(sweep(reg_dat, 2, a_itm, ’-’), 1, d_reg_itm, ’-’))
b_itm = stats::rnorm(rep(1, n_patient), ((B1/sigma2e_neg_itm)
+ (B2+B3+B4)/sigma2e_phr_itm + mu_b_itm/sigma2b_itm)/
(n_neg*(cc_itm^2)/sigma2e_neg_itm + (sum(pos_conc^2)+
colSums(matrix((rep(phi_itm, each = n_hk) +
kappa_hk_itm)^2, nrow = n_hk))+ colSums(matrix((rep(phi_itm, each = n_reg) +
kappa_reg_itm)^2, nrow = n_reg)))/sigma2e_phr_itm + 1/sigma2b_itm),
sqrt(1/(n_neg*(cc_itm^2)/sigma2e_neg_itm + (sum(pos_conc^2)+
colSums(matrix((rep(phi_itm, each = n_hk) + kappa_hk_itm)^2,
nrow = n_hk))+ colSums(matrix((rep(phi_itm, each = n_reg) + kappa_reg_itm)^2, nrow
=
n_reg)))/sigma2e_phr_itm + 1/sigma2b_itm)))
}
cc_itm = truncnorm::rtruncnorm(1, -6, -1, sum(sweep(sweep(sweep(neg_dat, 2, a_itm,
’-’), 1, d_neg_itm, ’-’), 2, b_itm, ’*’))/ (n_neg * sum(b_itm^2)),
sqrt(sigma2e_neg_itm/(n_neg * sum(b_itm^2))))
phi_itm = numeric(n_patient)
phi_itm[1:(n_patient - 1)] = truncnorm::rtruncnorm(rep(1, n_patient),
phi_L, phi_U, (colSums(hk_dat-matrix(rep(a_itm, each = n_hk) +
rep(b_itm, each = n_hk) * kappa_hk_itm + rep(d_hk_itm, n_patient), nrow = n_hk))+
colSums(reg_dat-matrix(rep(a_itm, each = n_reg) + rep(b_itm, each = n_reg) *
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kappa_reg_itm + rep(d_reg_itm, n_patient), nrow = n_reg)))/ ((n_hk+n_reg)*b_itm),
sqrt(sigma2e_phr_itm/((b_itm^2) * (n_hk+n_reg))))[-n_patient]
phi_itm[n_patient] = -sum(phi_itm)
kappa_hk_itm = stats::rnorm(rep(1, n_patient * n_hk), ((rep(b_itm,
each = n_hk)*(unlist(hk_dat) - rep(a_itm, each = n_hk) - rep(b_itm*phi_itm, each =
n_hk) - rep(d_hk_itm, n_patient)))/ sigma2e_phr_itm +
rep(lambda_hk_itm, n_patient)/sigma2kappa_hk_itm)/
rep((b_itm^2)/sigma2e_phr_itm + 1/sigma2kappa_hk_itm, each = n_hk),
sqrt(rep(1/((b_itm^2)/sigma2e_phr_itm + 1/sigma2kappa_hk_itm), each = n_hk)))
kappa_reg_itm = stats::rnorm(rep(1, n_patient * n_reg), ((rep(b_itm,
each = n_reg)*(unlist(reg_dat) - rep(a_itm, each = n_reg) -
rep(b_itm*phi_itm, each = n_reg) - rep(d_reg_itm, n_patient)))/
sigma2e_phr_itm + rep(lambda_reg_itm, n_patient)/sigma2kappa_reg_itm)/
rep((b_itm^2)/sigma2e_phr_itm + 1/sigma2kappa_reg_itm, each = n_reg),
sqrt(rep(1/((b_itm^2)/sigma2e_phr_itm + 1/
sigma2kappa_reg_itm), each = n_reg)))
lambda_hk_itm = truncnorm::rtruncnorm(rep(1, n_hk), lambda_hk_range[1,],
lambda_hk_range[2,], rowMeans(matrix(kappa_hk_itm, nrow = n_hk)),
sqrt(sigma2kappa_hk_itm/n_patient))
lambda_reg_itm = truncnorm::rtruncnorm(rep(1, n_reg), lambda_reg_range[1,],
lambda_reg_range[2,], rowMeans(matrix(kappa_reg_itm, nrow = n_reg)),
sqrt(sigma2kappa_reg_itm/n_patient))
d_neg_itm = stats::rnorm(n_neg, rowSums(sweep(neg_dat, 2, a_itm + cc_itm*
b_itm, ’-’)/sigma2e_neg_itm)/(n_patient/sigma2e_neg_itm + 1/sigma2d_neg_itm),
sqrt(1/(n_patient/sigma2e_neg_itm + 1/sigma2d_neg_itm)))
d_pos_itm = stats::rnorm(n_pos, rowSums(sweep(pos_dat-pos_conc %o% b_itm, 2,
a_itm, ’-’)/
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sigma2e_phr_itm)/(n_patient/sigma2e_phr_itm + 1/sigma2d_phr_itm),
sqrt(1/(n_patient/sigma2e_phr_itm + 1/sigma2d_phr_itm)))
d_hk_itm = stats::rnorm(n_hk, rowSums(sweep(hk_dat-matrix(rep(b_itm,
each = n_hk)*(rep(phi_itm, each = n_hk)+kappa_hk_itm),nrow = n_hk),
2, a_itm, ’-’)/sigma2e_phr_itm)/ (n_patient/sigma2e_phr_itm +
1/sigma2d_phr_itm), sqrt(1/(n_patient/sigma2e_phr_itm + 1/sigma2d_phr_itm)))
d_reg_itm = stats::rnorm(n_reg, rowSums(sweep(reg_dat-matrix(rep(b_itm,
each = n_reg)*(rep(phi_itm, each = n_reg)+kappa_reg_itm),nrow = n_reg),
2, a_itm, ’-’)/sigma2e_phr_itm)/ (n_patient/sigma2e_phr_itm + 1/sigma2d_phr_itm),
sqrt(1/(n_patient/sigma2e_phr_itm + 1/sigma2d_phr_itm)))
mu_a_itm = stats::rnorm(1, (sum(a_itm)/sigma2a_itm +
mu_a_mu/sigma2_mu_a)/(n_patient/sigma2a_itm + 1/sigma2_mu_a),
sqrt(1/(n_patient/sigma2a_itm + 1/sigma2_mu_a)))
mu_b_itm = stats::rnorm(1, (sum(b_itm)/sigma2b_itm +
mu_b_mu/sigma2_mu_b)/(n_patient/sigma2b_itm + 1/sigma2_mu_b),
sqrt(1/(n_patient/sigma2b_itm + 1/sigma2_mu_b)))
sigma2e_neg_itm = 1/stats::rgamma(1, u + n_patient*n_neg/2, v+sum(sweep(sweep(
neg_dat, 2, a_itm + b_itm*cc_itm, ’-’), 1, d_neg_itm, ’-’)^2)/2)
sigma2e_phr_itm = 1/stats::rgamma(1, u+n_patient*(n_pos+n_hk+n_reg)/2,
v+ (sum(sweep(sweep(pos_dat - pos_conc %o% b_itm, 2, a_itm,
’-’), 1, d_pos_itm, ’-’)^2)+ sum(sweep(hk_dat - matrix(rep(a_itm,
each = n_hk) + rep(b_itm, each = n_hk) * (rep(phi_itm, each = n_hk) + kappa_hk_itm),
nrow = n_hk), 1, d_hk_itm, ’-’)^2)+ sum(sweep(reg_dat - matrix(rep(a_itm, each =
n_reg) + rep(b_itm,
each = n_reg) * (rep(phi_itm, each = n_reg) + kappa_reg_itm),
nrow = n_reg), 1, d_reg_itm, ’-’)^2))/2)
sigma2a_itm = 1/stats::rgamma(1, u + n_patient/2,
v + sum((a_itm - mu_a_itm)^2)/2)
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sigma2b_itm = 1/stats::rgamma(1, u + n_patient/2,
v + sum((b_itm - mu_b_itm)^2)/2)
sigma2kappa_hk_itm = 1/stats::rgamma(1, u + n_patient*n_hk/2, v +
sum((kappa_hk_itm - rep(lambda_hk_itm, n_patient))^2)/2)
sigma2kappa_reg_itm = 1/stats::rgamma(1, u + n_patient*n_reg/2, v +
sum((kappa_reg_itm - rep(lambda_reg_itm, n_patient))^2)/2)
cat(paste(round(sigma2kappa_reg_itm, 3),”))
sigma2d_neg_itm = 1/stats::rgamma(1, u + n_neg/2, v + sum(d_neg_itm^2)/2)
sigma2d_phr_itm = 1/stats::rgamma(1, u + n_pos/2, v + sum(d_pos_itm^2)/2)
if(i > warmup)
{ j = i - warmup
aa[j,] = a_itm
bb[j,] = b_itm
cc[j] = cc_itm
phi_return[j,] = phi_itm
kappa_hk[j,] = kappa_hk_itm
kappa_reg[j,] = kappa_reg_itm
lambda_hk[j,] = lambda_hk_itm
lambda_reg[j,] = lambda_reg_itm
d_neg[j,] = d_neg_itm
d_pos[j,] = d_pos_itm
d_hk[j,] = d_hk_itm
d_reg[j,] = d_reg_itm
mu_a[j] = mu_a_itm
mu_b[j] = mu_b_itm
sigma2e_neg[j] = sigma2e_neg_itm
sigma2e_phr[j] = sigma2e_phr_itm
sigma2a[j] = sigma2a_itm
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sigma2b[j] = sigma2b_itm
sigma2kappa_hk[j] = sigma2kappa_hk_itm
sigma2kappa_reg[j] = sigma2kappa_reg_itm
sigma2d_neg[j] = sigma2d_neg_itm
sigma2d_phr[j] = sigma2d_phr_itm } }
#get the mcmc samples of key parameters.
mcmc.samples = list(aa = aa, bb = bb, d_pos = d_pos, d_neg = d_neg,
cc = cc, mu_a = mu_a, mu_b = mu_b, phi = phi_return, kappa_reg
= kappa_reg, d_hk = d_hk, sigma2a = sigma2a, sigma2b = sigma2b,
sigma2kappa_reg = sigma2kappa_reg, sigma2kappa_hk = sigma2kappa_hk,
sigma2e_neg = sigma2e_neg, sigma2e_phr = sigma2e_phr, sigma2d_neg
= sigma2d_neg, sigma2d_phr = sigma2d_phr)
#calculate summary statistics for the parameters.
kappa_reg = matrix(colMeans(kappa_reg), nrow = n_reg)
kappa_hk = matrix(colMeans(kappa_hk), nrow = n_hk)
cc = mean(cc)
lambda = c(colMeans(lambda_hk), colMeans(lambda_reg))
mu_a = mean(mu_a)
mu_b = mean(mu_b)
phi = colMeans(phi_return)
sigma2a = stats::median(sigma2a)
sigma2b = stats::median(sigma2b)
sigma2kappa_hk = stats::median(sigma2kappa_hk)
sigma2kappa_reg = stats::median(sigma2kappa_reg)
sigma2e_neg = stats::median(sigma2e_neg)
sigma2e_phr = stats::median(sigma2e_phr)
sigma2d_neg = stats::median(sigma2d_neg)
sigma2d_phr = stats::median(sigma2d_phr)
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print(proc.time() - ptm)
return(list(mu_a = mu_a, mu_b = mu_b, cc = cc, lambda = lambda, phi = phi,
kappa_hk = kappa_hk, kappa_reg = kappa_reg, sigma2a = sigma2a, sigma2b = sigma2b,
sigma2kappa_hk = sigma2kappa_hk, sigma2kappa_reg = sigma2kappa_reg, sigma2d_neg
= sigma2d_neg, sigma2d_phr = sigma2d_phr, sigma2e_neg = sigma2e_neg, sigma2e_phr
= sigma2e_phr))
}
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